

CV dott. Filippo Pietrantonio - 2025 -

Curriculum Vitae

Dettagli Personali

Nome e Cognome Filippo Pietrantonio, MD
Indirizzo lavorativo: Via Venezian, 1 -20133 Milano - Italia
E-mail: filippo.pietrantonio@istitutotumori.mi.it

Incarichi attuali:

01/02/2024 - presente Direttore della s.s. Oncologia medica gastroenterologica, afferente alla s.c. Oncologia medica 1 presso Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Comitati Scientifici e Boards

13/06/2025 – 12/06/2028 Membro del Comitato Editoriale per The Oncologist - sezione Cancro Gastrointestinale, Oncologia medica.
22/05/2025 – 21/05/2027 Membro del team editoriale del giornale "Annals of Oncology" nella funzione di "Editorial Lead" per i tumori Gastrointestinali.
01/03/2025 – 28/02/2028 Membro dell' Annual Meeting Scientific Program Committee per ASCO. L'intento del Comitato è sviluppare il programma scientifico di meeting annuali rivedendo e giudicando gli abstract presentati e selezionando gli abstract per le presentazioni e pubblicazione in concomitanza dei meeting e sviluppando sessioni scientifiche
21/06/2024 – presente Membro Gruppo di Lavoro AIOM-SIF per l'aggiornamento delle Raccomandazioni per analisi farmacogenetiche relative a DPD e fluoropirimidine
01/02/2024 – presente Revisore "Linee Guida Sindromi di predisposizione ereditaria ai tumori" (AIOM - Associazione Italiana di Oncologia Medica)
01/10/2023 – presente Coordinatore Linee Guida Nazionali AIOM Tumori dell'Esofago
31/10/2021 - presente Membro del Consiglio Direttivo Nazionale AIOM (Associazione Italiana di Oncologia Medica)
01/01/2020 - presente Segretario Scientifico e Membro del Comitato Esecutivo di Fondazione G.O.N.O. (Gruppo Oncologico del Nord Ovest)
01/01/2019 - presente Membro della Task-Force "Upper Gastrointestinal Cancer" and "Colorectal Cancer" European Organisation for Research and Treatment of Cancer (EORTC) - Principal Investigator presso Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
01/01/2016 - presente Membro del Gruppo di Lavoro "Colorectal Cancer" ACC (Alliance against Cancer)
01/01/2019 – 01/01/2020 Membro del Boards of Directors di Fondazione G.O.N.O. (Gruppo Oncologico del Nord Ovest).

Membro di Associazioni

04/01/2021 - presente ASCO (American Society of Clinical Oncology)
01/01/2012 - presente ESMO (European Society for Medical Oncology)
01/01/2012 - presente AIOM (Associazione Italiana di Oncologia Medica)

Revisore di Testate scientifiche

01/01/2012 - presente Annals of Oncology, Cancer, JAMA, British Journal of Cancer, Nature Reviews in Clinical Oncology, European Journal of Cancer, Cancer Research, Clinical Cancer Research, The Lancet Oncology, Journal of Clinical Oncology, Annals of Surgery, JCO Precision Oncology, Journal of Immunotherapy of Cancer, Gastric Cancer, Nature Communications, International Journal of Cancer, Clinical Colorectal Cancer,.

Incarichi precedenti:

03/ 2018 - 31/01/2024 Dirigente medico, s.c. Oncologia Medica 1, Unità di Oncologia Gastrointestinale presso Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
31/10/2019 - 31/10/2021 Membro del del Consiglio Direttivo Nazionale AIOM Lombardia (Associazione Italiana di Oncologia Medica).
01/03/2018 - 01/07/2021 Ricercatore - Università degli Studi di Milano-affiliato con il Dipartimento di Oncologia Medica – Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
01/10/2011 - 28/02/2018 Consulente nell'Unità di Oncologia Medica 1 – Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
01/10/2015 - 01/10/2017 Membro del Comitato "Young Working Group" AIOM (Associazione Italiana di Oncologia Medica).

Qualifiche accademiche / Training

31/05/2021 Professore di I fascia - Abilitazione Scientifica Nazionale
09/07/2020 Professore di II fascia - Abilitazione Scientifica Nazionale
02/09/2011 Specializzazione in Oncologia Medica presso Università degli Studi di Milano, Italy. Summa cum laude con tesi dal titolo: "Phase II study - adjuvant chemoradiotherapy treatment with chronomodulated capecitabine in patients with high-risk rectal cancer".
08/03/2007 Registrato presso Albo dei Medici (Parma, Italia) N°5878
15/02/2007 Abilitazione Medica
23/10/2006 Laurea in Medicina e Chirurgia (MD) Università di Parma Italy. Summa cum laude con tesi dal titolo: "Role of the HER-2 /NEU oncogene in the etiopathogenesis of non-small cell lung cancer in patients with chronic lymphatic leukemia"

CV dott. Filippo Pietrantonio - 2025 -

Interessi di ricerca

Filippo Pietrantonio, MD, è un clinico e ricercatore oncologo per i tumori gastrointestinali (prevalentemente tumori del colon retto e gastrici). La sua principale attività è rivolta a disegnare studi clinici e di medicina traslazionale. L'esperienza di ricerca del Dott. Pietrantonio include vari studi clinici di fase I-II e III in tumori del colon retto e gastrico.

Research Grants Ricevuti

26/11/2024	AIRC Investigator Grant 2024 –Grant di Ricerca : “ Actioning the resistance mechanisms to different antibody-drug conjugates in gastric cancer” “. Grant holder F. Pietrantonio € 1.100.000€
25/03/2022	Contributo per lo sviluppo della ricerca istituzionale 2021 Fondazione IRCCS Istituto Nazionale dei Tumori - Grant di ricerca " Window-of-opportunity umbrella trial as a translational platform for short-course pre-operative targeted treatments in non-metastatic resectable colorectal cancer: the UNICORN study " Grant holder F. Pietrantonio - € 814.000
14/10/2020	Ministero della Salute – Ricerca Finalizzata 2019 “Change Promoting”. “Temozolomide and irinotecan regimen as liquid biopsy-guided non-cross resistant sequential adjuvant treatment of patients with MGMT methylated, microsatellite stable colorectal cancer failing to achieve seroreversion after a standard adjuvant strategy “ - Grant holder F. Pietrantonio - € 449.600
02/01/2020	AIRC Investigator Grant 2019 - Grant di ricerca: "Moving forward from single-agent trastuzumab thanks to a reverse translational approach in HER2+ advanced gastric cancer" Grant holder F. Pietrantonio € 746.000
01/01/2019	Contributo per lo sviluppo della ricerca 2018 Fondazione IRCCS Istituto Nazionale dei Tumori - Grant research "Exploiting Liquid Biopsy To Predict Outcomes And Progression Patterns In Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcr) Patients Randomized To Either 5-Fu/Lv Plus Panitumumab Or Panitumumab Alone As Maintenance Strategy Following Folfox Plus Panitumumab Induction: A Pre-Planned Translational Analysis Of The Valentino Study" Grant holder F. Pietrantonio - € 40.000
06/04/2018	Università degli Studi di Milano Dipartimento di Oncologia e Emato-Oncologia Research Support Plan 2018 - Line 2: – Grant research: "Molecular profiling of HER2 positive metastatic gastric cancer patients with exceptional response to trastuzumab-based therapy" - Grant holder F. Pietrantonio - € 28.000

Honor Awards

16/11/2018	Award AIOM 2018 “Lecture Marco Venturini” 2018: "ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
01/01/2016	Award "Marzia Galli Kienle" "Met-Driven resistance to dual EGFR and BRAF blockade may be overcome by Switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer"- Cancer Discovery, 2016
01/01/2016	Nota di merito- Welfare Department of Lombardy
30/06/2014	Award “Young Researcher” Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Attività di Insegnamento

11/10/2024 – in corso	Mentore per “ESMO Virtual Mentorship Programme 2024-2025”
2023 - 2024	Mentore per I Mercoledì di AIOM
2017 – in corso	Tutor per studenti in medicina - Università degli Studi di Milano
2014 - in corso	Co-Advisor per tesi - per studenti in medicina - Università degli Studi di Milano
2019 - 2021	Scuola di specializzazione in Ortopedia e Traumatologia - Università degli Studi di Milano - Corso di Oncologia Medica.
2019 - 2021	Master in Medicina e Chirurgia - Università degli Studi di Milano - Corso di Oncologia Medica.
2019 - 2021	Master In Biotecnologia Medica e Medicina Molecolare - Università degli Studi di Milano - Corso di Oncologia Medica.
2018 - 2021	Scuola di specializzazione in Oncologia Medica - Università degli Studi di Milano - Corso di Oncologia Medica.
2018 - 2021	Scuola di specializzazione in Neurochirurgia - Università degli Studi di Milano - Corso di Oncologia Medica.

Trials

Il Dott. Pietrantonio ha disegnato vari studi accademici no-profit tra cui:

- Assessing the correlation between pathological response to neoadjuvant chemotherapy and event-free survival in patients with resectable gastric or gastroesophageal junction adenocarcinoma" (LONGEVITY).
- NCT06037980 phase II/III randomized clinical trial of CisPlatin pLUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patlents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study
- NCT06253650 Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNlmal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study (TRINITY)
- NCT05845450 Window-of-opportunity umbrella trial as a translational platform for short-course pre-operative targeted treatments in non-metastatic resectable colorectal cancer (UNICORN).
- NCT04817826: TremellImumab aNd Durvalumab For the Non-operative Management (NOM) of MSI-high Resectable GC/GEJC. (Infinity)
- NCT05594290: Window-of-opportunity study of chemo-immunotherapy in patients with resectable MERkel Cell carcinoma prior to sUrgeRY: the MERCURY trial (MERCURY)
- NCT05031975: Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy (Eraze-TMZ)
- NCT05136326: Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer (CATARTIC)
- NCT04689347: 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer (FLIRT-bev)
- NCT03832621: NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (Maya)
- NCT02476045: Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)
- NCT02934464: Assessment of Ramucirumab plus paclitaxel as switch MANTelnance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers (ARMANI phase III study) – Trial Alias: H7T-IT-O004
- NCT02414009: Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients (CAPTEM)
- NCT02086656: Perioperative treatment with COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) of high risk or borderline resectable colorectal cancer liver metastasis (COI-B)

Dr. Pietrantonio ha preso parte e prende parte come Membro di alcuni Steering Committee di studi come:

- 2025-2026: CLARITY Gastric02 - AstraZeneca
- 2024-2025: JNJ-61186372 (amivantamab)- OrigAMI-2 - Janssen Research & Development
- 2024: AMG 193 Study 20210023 - Amgen

Dr. Pietrantonio è un Membro dell' Independent Data Monitorng Committee per :

- 2023-2025: A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) (ARIEL) Study - Eudract number: 2021-003330-36 - Chief Investigator: Jenny Seligmann - Professor of University of Leeds.

Dr. Pietrantonio è anche Capo dell'Independent Data Monitorng Committee per:

- 2024- ongoing: ZODIAC: A randomised phase II study of Zimberelimab anti-PD1 immunOtherapy +/- Domvanalimab anti-TIGIT immunotherapy in resectable mismatch repair deficient gastric and gastro-oesophageal junctional AdenoCarcinoma - Clinical trials.gov Number: NCT06250036 - Chief Investigator: Dr. Naureen Starling - Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.

Il Dott. Pietrantonio gestisce svariati studi profit e no-profit tra cui:

2025 Principal Investigator: "ComPrehensive evaluation and biomarker study of OxalipLATin-related peripheRal sensory neuropathy in patients with gastrointestinal cancers: the POLAR study". Promoter Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

CV dott. Filippo Pietrantonio - 2025 -

- 2025 Principal Investigator: "RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)". (RMC-6236). Promoter Revolution Medicines, Inc.
- 2025 Principal Investigator: "Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreak 301)". Promoter Amgen Inc.
- 2025 Sub- Investigator: "Encorafenib+Cetuximab beyond progression in combination with Folfiri in patients with BRAF V600E mutated metastatic colorectal cancer progressing on Encorafenib + Cetuximab.". (ECLYPSE). Promoter Fondazione Policlinico Universitario Agostino Gemelli, IRCCS
- 2024 Sub- Investigator: "Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in huge (PCI>28) Pseudomyxoma Peritonei (PMP) Patients Candidates to Cytoreductive Surgery (CRS) and Hypertermic Intraperitoneal Chemotherapy (HIPEC)" (REVERSE). Promoter Fondazione IRCCS Istituto Nazionale dei tumori di Milano
- 2024 Principal Investigator: "A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers". (MK-1022-011). Promoter Merck Sharp & Dohme Corp
- 2024 Principal Investigator: "A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D". (MK-3475-06D). Promoter Merck Sharp & Dohme Corp.
- 2024 Principal Investigator: "A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C". (MK-3475-06C). Promoter Merck Sharp & Dohme Corp.
- 2024 Sub-Investigator: "An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer". (JZP598-302). Promoter Jazz Pharmaceuticals
- 2024 Sub-Investigator: "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)". (D7025C00001). Promoter AstraZeneca S.p.A
- 2024 Sub- Investigator: "A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)" . (TT420C2308 / FIRST-308). Promoter TRANSTHERA BIOSCIENCE
- 2024 Principal Investigator: "Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction /gastric cancer" . (CL1-95029-002). Promoter Institut de Recherches Internationales Servier (I.R.I.S.)
- 2024 Principal Investigator: "A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)" . (MK2870-015). Promoter Merck Sharp & Dohme LLC
- 2024 Principal Investigator: "A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers" . (MK9999-02A). Promoter Merck Sharp & Dohme LLC
- 2024 Principal Investigator: "A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors" . (NOUS-209-1). Promoter Nouscom S.r.l.
- 2024 Principal Investigator: "Phase III randomized study of FOLFOXIRI plus BEVACIZUMAB and ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable pMMR and Immunoscore IC-high metastatic colorectal cancer patients" . (Atezotribe 2). Promoter GONO Foundation
- 2024 Principal Investigator: "Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)". Promoter Gruppo Oncologico dell'Italia Meridionale (GOIM)
- 2024 Principal Investigator: "Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAFV600E mutated mCRC.." (BRICKET). Promoter GONO Foundation
- 2024 Principal Investigator: "Phase II study evaluating holmium-166 TARE followed by maintenance therapy in liver limited unresectable colorectal cancer patients after first-line chemotherapy and target agents." (HAITI)". Promoter GONO Foundation

CV dott. Filippo Pietrantonio - 2025 -

-
- 2024 Sub- Investigator: "Assessing the correlation between pathological response to neoadjuvant chemotherapy and event-free survival in patients with resectable gastric or gastroesophageal junction adenocarcinoma" (LONGEVITY). Promoter GONO Foundation
 - 2024 Sub- Investigator: "Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNimal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study" (TRINITY). Promoter GONO Foundation
 - 2023 Principal Investigator: "An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer" . (SGNTUC-029 (MOUNTANEER)). Promoter Seagen Inc.
 - 2023 Sub-Investigator: "Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC)". (PANDORA) Promoter Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
 - 2023 Sub-Investigator: "A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patlents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study)". Promoter GONO Foundation
 - 2023 Sub-Investigator: "An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProviDHe)". Promoter Institut de Recherches Internationales Servier (I.R.I.S.)
 - 2023 Principal Investigator: "A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors". (CA043-001) Promoter Bristol-Myers Squibb Research and Development.
 - 2023 Principal Investigator: "Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and resectable primary colorectal cancer: the UNICORN study". Promoter GONO Foundation.
 - 2023 Principal Investigator: "A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer". Promoter Agenesis, Inc.
 - 2023 Principal Investigator: "A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/ leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated unresectable metastatic colorectal cancer" (NuTide:323) Promoter NuCana plc
 - 2023 Principal Investigator: "Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line." (CAPRI-2). Promoter Gruppo Oncologico dell'Italia Meridionale (GOIM).
 - 2023 Sub-Investigator: "A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer" (Azur). Promoter GlaxoSmithKline Research & Development Limited.
 - 2023 Principal Investigator: "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer" (Origami). Promoter Janssen-Cilag SpA.
 - 2022 Principal Investigator: "A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)". Promoter Zymeworks Inc.
 - 2022 Sub-Investigator: "Window-of-opportunity study of chemo-immunotherapy in patients with resectable MERkel Cell carcinoma prior to sUrgeRY: the MERCURY trial". Promoter Fondazione GONO
 - 2022 Principal Investigator "A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression" (FORTITUDE-102). Promoter Amgen Inc.
 - 2022 Principal Investigator: "CAVE-2 (Cetuximab-AVElumab) mCRC: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients." (CAVE-2) Promoter Gruppo Oncologico dell'Italia Meridionale (GOIM).
 - 2022 Principal Investigator "A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B (MK06B). Promoter Merck Sharp & Dohme Corp.

CV dott. Filippo Pietrantonio - 2025 -

-
- 2022 Principal Investigator "A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A"(MK06A). Promoter Merck Sharp & Dohme Corp.
 - 2022 Principal Investigator: "Exploiting circulating tumour DNA to intensify the postoperative treatment of stage III and high-risk stage II resected colon cancer patients with adjuvant FOLFOXIRI and/or post-adjuvant Trifluridine/Tipiracil (ERASE-CRC) Promoter Fondazione GONO.
 - 2022 Principal Investigator: "A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer Brief Title: A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)" Promoter Bristol-Myers Squibb Company
 - 2022 Principal Investigator "A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation".(219-01-72). Promoter Amgen Inc.
 - 2022 Sub-Investigator "A phase 2/3 study of ALX148 in patients with advanced HER2-overexpressing gastric/gastroesophageal junction adenocarcinoma". Promoter ALX-Oncology Inc. (ASPEN-06)
 - 2022 Principal Investigator "daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)" Promoter Novartis Farma S.p.A.
 - 2021 Co-Investigator Profit Study "A global, multicenter, randomized, placebocontrolled phase 3 trial to compare the efficacy and safety of fruquintinib plus best supportive care to placebo plus best supportive care in patients with refractory metastatic colorectal cancer (FRESCO-2)" Promoter Hutchison MediPharma Limited, Coordinating Center Ospedale Policlinico San Martino - IRCCS per l'Oncologia.
 - 2021 Principal Investigator "A phase 1/2 study exploring the safety and activity of trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients" Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
 - 2021 Principal Investigator No-profit Study "Prospective observational study investigating the role of liquid biopsy and patients-derived organoids (PDOs) as novel tools for assessing tumor biology and acquired drug resistance in patients with tumors of the gastrointestinal and bilio-pancreatic tract, neuroendocrine tumors and Merkel cell carcinomas" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2021 Principal Investigator "An open-label, single-arm, phase IB/IIA trial to evaluate the safety and efficacy of the EP4 receptor antagonist CR6086 in combination with the PD-1 inhibitor balstilimab (AGEN2034), in patients with pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer". Promoter Rottapharm Biotech S.r.l., Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2021 Principal Investigator "A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)" Promoter Merck Sharp & Dohme Corporation, Coordinating Center Istituto Nazionale Tumori IRCCS - Fondazione Pascale Napoli
 - 2021 Principal Investigator No-Profit Study "Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in Liquid Biopsy to compare in first-line therapy FOLFIRI plus Cetuximab or Bevacizumab (LIBImAb Study)" Promoter Azienda USL-IRCCS di Reggio Emilia, Coordinating Center Azienda USL-IRCCS di Reggio Emilia
 - 2021 Principal Investigator "A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers" Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
 - 2021 Principal Investigator No-Profit Study "Analysis of biomarkers predicting sensitivity to immuno checkpoint inhibitors in patients with colon cancer MSI-H or with MSI-H-like phenotype after treatment with temozolomide" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2021 Principal Investigator No-Profit Study "Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2021 Principal Investigator Profit Study "A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma" Promoter Merck Sharp & Dohme Corporation, Coordinating Center Policlinico Universitario Gemelli (RM)

CV dott. Filippo Pietrantonio - 2025 -

-
- 2021 Principal Investigator Profit Study "A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)" Promoter Merck Sharp & Dohme Corporation, Coordinating Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - Meldola (FC)
 - 2021 Principal Investigator Profit Study "A Phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2 positive locally advanced unresectable or metastatic colorectal cancer (DESTINY-CRC02)" Promoter Daichi Sankyo Inc, Coordinating Center ASST Grande Ospedale Metropolitano Niguarda – Milano
 - 2021 Co-Investigator Profit Study "A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)" Promoter Incyte Corporation, Coordinating Center Azienda Ospedaliera Universitaria della Università Vanvitelli di Napoli
 - 2021 Principal Investigator Profit Study "A phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after trastuzumab-containing regimen (DESTINY-GASTRIC04)" Promoter Incyte Corporation, Coordinating Center Azienda Ospedaliera Universitaria della Università Vanvitelli di Napoli
 - 2020 Principal Investigator No-profit Study "Randomized phase II study of panitumumab rechallenge followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients". Promoter GONO, Coordinating Center Azienda Ospedaliera Universitaria Pisana
 - 2020 Principal Investigator No-profit Study "Phase II Study on NIVolumab in combination with FOLFOXIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients" Promoter GOIRC, Coordinating Center Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia
 - 2020 Principal Investigator No-profit Study "Phase 1b trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2020 Principal Investigator No-profit Study "Tremellumab and durvalumab combination For the non-operative management (NOM) of Microsatellite Instability (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, Phase II INFINITY study" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2020 Principal Investigator No-profit Study "Tumor and circulating biomarkers and their correlation with outcomes after priming with temozolomide and treatment with temozolomide, nivolumab and ipilimumab at low doses in patients treated within the institutional non-profit MAYA study" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2020 Principal Investigator No-profit Study "Retrospective observational study on the use of immunotherapy with anti-PD-1 antibodies in patients with MSI-H metastatic colorectal cancer" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2020 Principal Investigator No-profit Study "Observational study on the rate of AMNESIA panel positivity in the large dataset of gastric cancers collected at Foundation Medicine" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 - 2020 Principal Investigator No-profit Study "A master protocol empowering Precision Research in Colorectal Cancer (ALFAOMEGA)" Promoter IFOM - Fondazione Istituto FIRC di Oncologia Molecolare, Coordinating Center A.O. Ospedale Niguarda Ca' Granda (MI)
 - 2020 Co-Investigator Profit Study "A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)" Promoter Basilea Pharmaceutica International AG, Coordinating Center Istituto Europeo di Oncologia (IEO)
 - 2020 Principal Investigator Profit Study "A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)" Promoter AstraZeneca S.p.A., Coordinating Center Istituto Nazionale Tumori IRCCS "Fondazione Pascale" (NA)
 - 2020 Co-Investigator Profit Study "A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK- 3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative,

- previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)" Promoter Merck Sharp & Dohme Corporation, Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
- 2020 Co-Investigator Profit Study "A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)" Promoter Merck Sharp & Dohme Corporation, Coordinating Center ASST Papa Giovanni XXIII – Bergamo
- 2019 Principal Investigator No-profit Study "Post-surgical liquid biopsy- guided treatment of stage III and high-risk stage II colon cancer patients ". Promoter IFOM – Istituto FIRC di Oncologia Molecolare, Milano
- 2019 Principal Investigator No-profit Study "A master protocol empowering Precision Research in Colorectal Cancer" Promoter IFOM – Istituto FIRC di Oncologia Molecolare, Milano
- 2019 Principal Investigator No-profit Study "Phase II study of avelumab and cetuximab and modified folfoxiri as initial therapy for RAS wild-type unresectable metastatic colorectal cancer". Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
- 2019 Principal Investigator No-profit Study "A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting" Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
- 2019 Principal Investigator No-profit Study "Tracking the evolution of treatment resistance in the VALENTINO clinical trial." Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- 2019 Principal Investigator No-profit Study "Impact of radiomic biomarkers in predicting sensitivity to targeted therapy and molecular status in metastatic colorectal cancer" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- 2019 Principal Investigator No-profit Study "Predictive role of alternative promoters analysis by means of Signomax AP2000 platform in gastrointestinal and bilio-pancreatic cancers treated with immunotherapy" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- 2019 Co-Investigator Profit Study "A phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS-8201A) in HER2-Positive, unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen". Promoter DAICHI SANKIO DEVELOPMENT LIMITED, Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
- 2019 Co-Investigator No-Profit Study "A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer". Promoter Azienda Unità Sanitaria Locale della Romagna, Coordinating Center Azienda Unità Sanitaria Locale della Romagna
- 2019 Co-Investigator No-Profit Study "LIBIMET Trial: Redefining the risk of cancer relapse by serum metabolomic and ctDNA in patients with early stage colon cancer" Promoter USL Toscana Centro, Coordinating Center Ospedale Santo Stefano di Prato - Azienda USL Toscana Centro
- 2018 Principal Investigator No-profit Study "An observational itAlian MulticeNter study on molecular meccanismi of resistine to trAstuzumab in HER-2 positive gastric or gastroesophageal junction (GEJ) cancers: The AMNESIA study" Promoter e Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- 2018 Principal Investigator No-profit Study "Randomized phase II study of FOLFOXIRI plus BEVACIZUMAB plus ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable metastatic colorectal cancer" Promoter Gruppo GONO - Coordinating Center Azienda Ospedaliera Universitaria Pisana
- 2018 Principal Investigator No-profit Study "Randomized phase 2 trial of cetuximab and avelumab or avelumab alone for unresectable, locally advanced or metastatic squamous cell anal carcinoma (SCCAC) progressed after at least one line of systemic treatment" Promoter Gruppo GONO - Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
- 2018 Principal Investigator No-profit Study "NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC): the MAYA study" - Promoter Fondazione IRCCS Istituto Nazionale dei Tumori Milano - Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori Milano
- 2018 Principal Investigator No-profit Study "Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer" Promoter Gruppo GONO - Coordinating Center Fondazione Policlinico Universitario "A Gemelli" Università Cattolica del Sacro Cuore, Roma
- 2018 Principal Investigator No-profit Study "Pembrolizumab in mmmr-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status". Promoter IFOM – Istituto FIRC di Oncologia Molecolare, Milano

-
- 2018 Co-Investigator No-Profit Study "Prospective and retrospective observational study, multicentric, of evaluation of the FLOT pattern as a perioperative treatment in gastric adenocarcinoma and gastroesophageal Junction (RealFLOT)" Promoter GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), Coordinating Center Azienda Ospedaliero Universitaria Careggi, Firenze
 - 2018 Co-Investigator Profit Study "A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma" Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
 - 2018 Co-Investigator No-Profit Study "A phase II trial of rechallenge with panitumumab driven by ras clonal-mediated dynamic of resistance. the chronos trial." Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO), Coordinating Center Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
 - 2018 Co-Investigator No-Profit Study "Multiplex genotyping of metastatic colorectal cancer patients for precision medicine trials. The FUNNEL Trial" Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO), Coordinating Center Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
 - 2018 Co-Investigator no-Profit Study "Adjuvant capecitabine in high risk pseudomyxoma peritonei patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)". Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
 - 2018 Co-Investigator no-Profit Study "Phase II multicentre trial of perioperative chemotherapy in operable patients with gastric cancer (Periscope trial)" Promoter Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Coordinating Center ASST of Cremona, Cremona
 - 2017 Co-Investigator Profit Study "A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer" Promoter Array BioPharma Inc, Coordinating Center Istituto Europeo di Oncologia (IEO)
 - 2017 Principal Investigator Profit Study "A Phase III, Randomized, Double-blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)" Promoter Merck Sharp & Dohme S.p.A, Coordinating Center Istituto Oncologico Veneto (IOV) – Padova
 - 2017 Principal Investigator Profit Study "A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma" Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
 - 2017 Co-Investigator Profit Study "A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BSC) compared to Placebo plus BSC in Patients with Advanced or Metastatic Gastric Cancer (GC)" Promoter LSK BioPartners, Inc., Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
 - 2017 Co-Investigator Profit Study "A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)" Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
 - 2017 Co-Investigator Profit Study "Randomized phase III study of triplet mFOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for unresectable RAS and BRAF wild-type metastatic colorectal cancer patients" Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
 - 2016 Co-Investigator no-Profit Study "The PANDA study: randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wildtype metastatic colorectal cancer elderly patients" Promoter Fondazione Gono Onlus
 - 2016 Co-Investigator Profit Study "A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs" Promoter Bristol-Myers Squibb International Corporation
 - 2016 Co-Investigator Profit Study "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma" Promoter Gilead Sciences, Inc
 - 2016 Co-Investigator Profit Study "CORRELATE - Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings" Promoter Bayer Healthcare AG
 - 2016 Co-Investigator Profit Study "A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or

- metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction” Promoter Merck KGaA
- 2016 Co-Investigator Profit Study “Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (I4T-MC-JVDD)” Promoter Eli Lilly Italia S.p.A.
- 2016 Co-Investigator No-Profit Study “Assessment of Ramucirumab plus paclitaxel as switch MANTelnance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2016 Co-Investigator Profit Study “A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma” Promoter F. Hoffmann-La Roche, Ltd
- 2016 Co-Investigator Profit Study “An open-label early access phase IIIb study of trifluridine / tipiracil (S95005/TAS-102) in patients with a pretreated metastatic colorectal cancer” Promoter Institut de Recherches Internationales Servier
- 2015 Co-Investigator no-Profit Study “Observational retrospective study on the use of ramucirumab (nominal use) in patients with gastric cancer and gastroesophageal junction, metastatic, progressed after a first-line therapy with platinum derivatives and fluoropyrimidine” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2015 Co-Investigator Profit Study “A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)” Promoter Eli Lilly Italia S.p.A.
- 2015 Co-Investigator Profit Study “Randomized, multi-center, open-label trial of pembrolizumab (MK-3475) versus paclitaxel in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination chemotherapy containing a platinum and a fluoropyrimidine agent” Promoter Merck Sharp & Dohme Corporation
- 2015 Co-Investigator no-Profit Study “Prospective study for the determination of the molecular profile of resistance to "target therapies" in patients with solid tumors - Protocol PROFILING” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
- 2015 Co-Investigator no-Profit Study “First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type, metastatic colorectal cancer: the VALENTINO study” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2015 Co-Investigator no-Profit Study “First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in first- and second-line treatment of unresectable metastatic colorectal cancer . The tribe-2 phase III study” Promoter Fondazione Gono Onlus
- 2015 Co-Investigator no-Profit Study “Explorative Evaluation of new potential prognostic factor in patient with gastrointestinal cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2015 Co-Investigator no-Profit Study “A phase II, randomized, multicenter study to assess the efficacy of nab-paclitaxel-based doublet as first line therapy in patients with cancer of unknown primary (CUP): the AGNOSTOS trial” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
- 2015 Co-Investigator no-Profit Study “A multicenter, translational study to investigate the genomic landscape of cancer of unknown primary (CUP): AGNOSTOS PROFILING study” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
- 2014 Co-Investigator Profit Study “A multicenter, phase II, single arm, two cohort study evaluating the efficacy, safety, and pharmacokinetics of AMG 337 in subjects with MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma or other MET amplified solid tumors” Promoter Amgen Dompè S.P.A.
- 2014 Co-Investigator no-Profit Study “Observational study on perioperative management with COI regimen (Capecitabine plus Oxaliplatin and Irinotecan) in patients with gastric or gastroesophageal locally advanced and technically resectable cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2014 Co-Investigator Profit Study “Identification and Characterization of Molecular and Clinical Profiles, and Outcomes in Subjects With MET-Amplified Cancers” Promoter Amgen Dompè S.P.A.
- 2014 Co-Investigator no-Profit Study “Activation of the druggable pathways in gastric carcinomas and clinical outcomes of metastatic patients treated with trastuzumab” Promoter Università di Urbino - Dipartimento Scienze Biomolecolari
- 2014 Co-Investigator Profit Study “A multi-centre randomized clinical trial of biomarker-driven maintenance treatment for first-line metastatic colorectal cancer (MODUL)” Promoter Roche S.p.A.
- 2014 Co-Investigator no-Profit Study “An open-label, randomized, multicenter, phase II trial designed to compare the

- efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2014 Co-Investigator no-Profit Study “Identificazione e caratterizzazione del DNA circolante nel sangue dei pazienti affetti da carcinoma colo-rettale avanzato e valutazione delle sue modificazioni nel corso del trattamento con cetuximab oppure panitumumab, associati o meno a chemioterapia” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2013 Co-Investigator no-Profit Study “Retrospective observational study on the use of off-label temozolomide in patients with metastatic colorectal cancer with methylation of the MGMT gene” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
- 2013 Co-Investigator no-Profit Study “A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction with Aflibercept in Combination with XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient” Promoter Sanofi-Aventis S.p.A.

Invitato come Relatore nei seguenti eventi più rilevanti

- 06-08/03/2025 JSMO Japan a Kobe, relatore nella: Sessione1: “Discussant for Symposium: New Multimodal treatment strategy for GI cancer”; Session 2: Relatore nel Simposio: “New Multimodal treatment strategy for GI cancer: - “NOM for lower GI cancer”
- 29/01/2025 Darmkrebs im Fokus: KRK25, relatore via webex per la Sessione “Colorectal Cancer Focus”
- 06-08/12/2024 ESMO ASIA Congress 2024, relatore in the Educational Session “Personalising gastrointestinal (GI) oncology: From old to new target inhibition”, giving the lecture: HER2 inhibition: Agnostic approach or disease-specific strategy?”
- 04-05/10/2024 European Chapter Congress of the International Gastric Cancer Association 2024 in Siena, as Member of the Scientific Committee for the event entitled: “The new frontiers of tailored approach and precision medicine for gastric/EGJ cancer”
- 26-29/06/2024 ESMO 2024 Monaco di Baviera, Talk within the “Multidisciplinary Tumor Board: Gastro Oesophageal Junction Cancer” Speaking about “A Case of MSI GE Junction Cancer”
- 30-4/06/2024 ASCO 2024 Chicago (USA) nell’ambito dell’ Oral Abstract Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary, the speech title is: “Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: the ARMANI phase III trial.”
- 30-1/12/2023 MSI Parigi, first meeting of 'SIRIC CURAMUS' dedicated to MSI Cancers. Within the session of Microsatellite Instability and Cancer, presentation in the second session "Understanding genomics": "Inducing MMR deficiency in MSS colorectal cancer".
- 20-24/10/2023 ESMO 2023 Madrid, during the Educational Session on “Biomarkers in metastatic colorectal cancer: What has changed in the last few years?” the speech title is “Biomarkers in the near future: What to expect?”. During the Presidential Symposium “LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study”.
- 6-7/10/2023 EGCC 2023 Ginevra (Svizzera), “Oligomestatic disease” Talk: MSI, PDL-1, HER2, Claudin 18.2 : which influence on treatment strategy; “European Chapter IGCA - Treatment Recommendation” Panel Discussion: Oligomestatic: Indications and Clinical Question”.
- 6-11/09/2023 ISDE 2023 Toronto (Canada), “Current and Future Status of Immunotherapy in Gastroesophageal Adenocarcinoma Session Details Innovative Approaches and Novel Systemic Therapies – When, Who, and Which?”; “Checkpoint Inhibition for Adenocarcinoma of the Esophagus and EGJ Session Details ISS - Immune-Oncology in Esophageal Cancer”; “Debate – Neoadjuvant Chemotherapy is the optimal approach for locally advanced esophageal adenocarcinoma Session Details Locally Advanced Esophageal Adenocarcinoma”.
- 27-1/07/2023 ESMO 2023 Barcellona within the Session X: Esophageal and Gastric Cancers: “Locally Advanced MSI-H Upper GI Cancer: What is the Optimal Approach?”
- 15-16/06/2023 UK Oncology Forum in Bristol (UK), “Making the most from Immunotherapy in gastroesophageal cancers - new targets, combinations and biomarkers”
- 18-24/01/2023 ASCO 2023 Annual Meeting , San Francisco (USA) Gastrointestinal Cancer Symposium INFINITY: a multi center, single-arm, multi color, phase II trial of tremelimumab and survalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)
- 13/04/2022 ESMO Deep Dive in Upper GI Cancers. “From biology to clinical experience in dMMR/MSI gastric cancer

CV dott. Filippo Pietrantonio - 2025 -

14/01/2022	ESMO Virtual Advanced Course on Innovation and Emerging Knowledge in Colorectal Cancer January 2022. "Treatment strategies in MSS/pMMR mCRC"
13/01/2022	ESMO Virtual Advanced Course on Innovation and Emerging Knowledge in Colorectal Cancer January 2022. "The relevance of stroma in CRC"
18/09/2021	Oral communication ESMO Annual Meeting 2021 "3830 - MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)"
04/09/2020	Speaker Immunotherapy in tumors of the gastrointestinal tract - Master of Immuno-oncology dell'Università La Sapienza, Roma.
31/01/2020	Member of the scientific committee and chair II Edition News in Oncology Focus on Gastrointestinal Tumors, Milano. Session "Upper GI cancer treatment".
15/11/2019	Speaker Seminar "Gastric carcinoma: clinical approach" IRCCS Istituto Candiolo (TO),
26/10/2019	Speaker XXI National Congress AIOM "Less frequent molecular alterations and feasible therapeutic opportunities in tumors of the stomach, biliary tract and pancreas".
29/09/2019	Oral Poster Discussion ASCO 2019 Annual Meeting, Chicago (USA) Gastrointestinal (Colorectal) Cancer Session "A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients"
17/01/2019	ASCO Gastrointestinal Cancers Symposium, sessione Cancers of The Esophagus and Stomach, San Francisco (CA). "Poster Walk" MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).
16/11/2018	Speaker XX Congresso Nazionale AIOM. "Mucinous neoplasms of the appendix - treatment"
07/11/2018	Speaker POST ESMO Congress -Woman for Oncology Italy, Padova. "Update colon-retto"
21/09/2018	Speaker National Congress SIC Società Italiana di Cancerologia 2018, Milano. "Evolving landscape of immunotherapy in colorectal cancer"
22/06/2018	Oral communication ESMO World Congress on Gastrointestinal Cancers, Barcelona, Spain. "First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in RAS wild-type metastatic colorectal cancer: the VALENTINO study"
05/06/2018	Oral communication ASCO Annual Meeting 2018, Colorectal Cancer Session. "First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer: The VALENTINO study".
30/06/2017	Oral communication ESMO World GI 2017, Barcellona. "RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC); abstract O-011. Ann Oncol (2017) 28 (suppl_3).
16/06/2017	Speaker AIOM post ASCO, Bologna. "Colorectal cancer poster review".
11/02/2017	Speaker AIOM post ASCO GI, Roma. "Colon cancer highlights".
29/10/2016	Member of the scientific committee and speaker XVIII National Congress AIOM, Roma educational session entitled: Colorectal cancer "Is there a role for biological characterization in adjuvant therapy?"
29/06/2016	Oral communication ESMO World GI 2016. "A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC) (Annals of Oncology, Volume 27, Issue suppl_2, 1 June 2016).
23/10/2015	Speaker and member of the scientific committee XVII National Congress AIOM: "To propose biologic maintenance to all patients after upfront treatment?"
27/10/2012	Speaker XIV Congresso Nazionale AIOM, Roma. "Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy".

Contributi Originali alla letteratura scientifica

(> 350 articoli tra cui pubblicazioni su riviste scientifica internazionali)

2025:

- Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamperi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A, Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Airo' Farulla L, Alessi A, Morano F, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, **Pietrantonio F.** Tremelimumab and durvalumab as neoadjuvant or

[non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO](#). Ann Oncol. 2025 Mar;36(3):285-296. doi: 10.1016/j.annonc.2024.11.016. Epub 2024 Dec 3. PMID: 39637944

- **Pietrantonio F**, Morano F, Niger M, Ghelardi F, Chiodoni C, Palazzo M, Nichetti F, Manca P, Cristarella E, Doldi V, Zaffaroni N, Sabella G, Brambilla N, Benincasa E, Giacobelli G, Vitalini C, Girolami F, Rovati LC. [The Prostaglandin EP4 Antagonist Vopibiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial](#). Clin Cancer Res. 2025 Feb 17;31(4):649-658. PMID: 39620921
- Nasca V, Zhao J, Ros J, Lonardi S, Zwart K, Cohen R, Fakih M, Jayachandran P, Roodhart JML, Derksen J, Intini R, Bergamo F, Mazzoli G, Ghelardi F, Ligerio M, Jonnagaddala J, Hawkins N, Ward RL, Wankhede D, Brenner H, Hoffmeister M, Vitellaro M, Salvatore L, Gallois C, Laurent-Puig P, Cremolini C, Overman MJ, Taieb J, Tougeron D, Andre T, Kather JN, Sundar R, Carmona J, Elez E, Koopman M, **Pietrantonio F**. [Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors](#). J Immunother Cancer. 2025 Feb 10;13(2):e010598. PMID: 39929672
- Antoniotti C, Carullo M, Rossini D, **Pietrantonio F**, Salvatore L, Lonardi S, Tamperi S, Sciortino C, Conca V, Calegari MA, Ciraci P, Tamburini E, Bergamo F, Boccaccio C, Passardi A, Ritorto G, Ugolini C, Aprile G, Galon J, Cremolini C. [Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study](#). ESMO Open. 2025 Feb;10(2):104135.esmoop.2025.104135. Epub 2025 Feb 4. PMID: 39908699
- Trahearn N, Sakr C, Banerjee A, Lee SH, Baker AM, Kocher HM, Angerilli V, Morano F, Bergamo F, Maddalena G, Intini R, Cremolini C, Caravagna G, Graham T, **Pietrantonio F**, Lonardi S, Fassan M, Sottoriva A. [Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcome](#). J Pathol. 2025 Feb;265(2):198-210. PMID: 39788558.
- Pretta A, Ziranu P, Perissinotto E, Ghelardi F, Marmorino F, Giampieri R, Puci M, De Grandis MC, Lai E, Nasca V, Ciraci P, Puzzoni M, Cerma K, Sciortino C, Taravella A, Pretta G, Giuliani L, Damonte C, Pusceddu V, Sotgiu G, Berardi R, Lonardi S, Bergamo F, **Pietrantonio F**, Cremolini C, Scartozzi M. [Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon](#). Br J Cancer. 2025 Feb;132(2):188-194. Epub 2024 Nov 27. PMID: 39604610
- Malapelle U, Angerilli V, Intini R, Bergamo F, Cremolini C, Grillo F, Guerini Rocco E, Latiano TP, Martinelli E, Normanno N, Pagni F, Parente P, Pastorino A, **Pietrantonio F**, Salvatore L, Lonardi S, Fassan M. [Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper](#). Crit Rev Oncol Hematol. 2025 Feb;206:104574. Epub 2024 Nov 22. PMID: 39581242
- Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, Tonegozzo P, Regondi V, Corsetto PA, **Pietrantonio F**, Mazzucchelli S, Corsi F, Belfiore A, Vingiani A, Pruneri G, Ligorio F, Colombo MP, Tagliabue E, Tripodo C, Vernieri C, Triulzi T, Pupa SM. [CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer](#). J Exp Clin Cancer Res. 2025 Jan 20;44(1):19. PMID: 39833955
- Vetere G, Germani MM, Antoniotti C, Salvatore L, **Pietrantonio F**, Lonardi S, Bensi M, Ghelardi F, Calegari MA, Intini R, Minelli A, Sullo FG, Boccaccio C, Taravella A, Puccini A, Lavacchi D, Noto L, Salati M, Scartozzi M, Cremolini C. [Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy](#). Ther Adv Med Oncol. 2025 Jan 7;17:17588359241299975. eCollection 2025. PMID: 39776534.
- Taieb J, Ambrosini M, Alouani E, Lonardi S, Sinicrope FA, Decraecker M, Boileve A, Hafliger E, Mazard T, Pernot S, Parent P, Ros J, Overman MJ, Jayachandran P, Nasca V, Salvatore L, Guimbaud R, Cremolini C, Tougeron D, **Pietrantonio F**. [Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors](#). J Immunother Cancer. 2025 Jan 4;13(1):e010424. PMID: 39755579
- Ghelardi F, Fucà G, Cavalli C, Shitara K, Cohen R, Ambrosini M, Maron SB, Cerantola R, Nasca V, Liberti GD, Zambelli L, Palazzo M, Salati M, Aoki Y, Kawazoe A, Cowzer D, Lonardi S, André T, Randon G, **Pietrantonio F**. [The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors](#). Dig Liver Dis. 2025 Jan;57(1):23-29. Epub 2024 May 21. PMID: 38772790

2024:

- Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hülle J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, Pusceddu S, Milione M, Morano F, **Pietrantonio F**, Pruneri G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M., [Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer](#). Cancer Med. 2024 Dec;13(23):e70393. PMID: 39618336
- Zhao JJ, Ong CJ, Srivastava S, Chia DKA, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay ST, Hagihara T, Tan ALK, Teo MCC, Tan QX, Ng G, Tan JW, Ng MCH, Gwee YX, Walsh R, Law JH, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh BT, Hong JH, Tay RYK, Teo CB, Dings MPG, Bijlsma M, Lum JHY, Mathur S, Pietrantonio F, Blum SM, van Laarhoven H, Klempner SJ, Yong WP, So JBY, Chen Q, Tan P, Sundar R. [Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases](#). Gastroenterology. 2024 Dec;167(7):1384-1398.e4. Epub 2024 Aug 13. PMID: 39147169

- Macagno M, Pessei V, Congiusta N, Lazzari L, Bellomo SE, Idrees F, Cavaliere A, **Pietrantonio F**, Raimondi A, Gusmaroli E, Zampino MG, Gervaso L, Ciardiello D, Mondello G, Santoro A, Personeni N, Bonoldi E, Aquilano MC, Valtorta E, Siena S, Sartore-Bianchi A, Amatu A, Bonazzina EF, Bencardino KB, Serini G, Marsoni S, Barault L, Di Nicolantonio F, Maione F. [A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection](#). *Diagnostics (Basel)*. 2024 Nov 5;14(22):2467.PMID: 39594133
- Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, Morano F, Niger M, Raimondi A, Prisciandaro M, Pircher CC, Sciortino C, Marchesi S, Garattini SK, Airò G, Miceli R, Di Bartolomeo M, **Pietrantonio F**. [Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer \(ARMANI\): a randomised, open-label, multicentre, phase 3 trial.](#) *Lancet Oncol*. 2024 Nov 15:S1470-2045(24)00580-1. Online ahead of print. PMID: 39557058
- Maspero M, Sposito C, Bongini MA, Cascella T, Flores M, Maccauro M, Chiesa C, Niger M, **Pietrantonio F**, Leoncini G, Bellia V, Bhoori S, Mazzaferro V. [Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study](#). *Transpl Int*. 2024 Oct 31;37:13641. eCollection 2024. PMID: 39544321
- Moretto R, Rossini D, Murgioni S, Ciraci P, Nasca V, Germani MM, Calegari MA, Vetere G, Intini R, Taravella A, Studiale V, Boccaccio C, Passardi A, Tamburini E, Zaniboni A, Salvatore L, **Pietrantonio F**, Lonardi S, Masi G, Cremolini C. [KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration](#). *JCO Precis Oncol*. 2024 Nov;8:e2400329. Epub 2024 Nov 7. PMID: 39509668
- Provenzano L, Gwee YX, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao JJ, Chia DKA, Yong WP, Tan P, So J, Kim G, Shabbir A, Ong CJ, Casella F, Cremolini C, Bencivenga M, Sundar R, **Pietrantonio F**. [Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden](#). *Ther Adv Med Oncol*. 2024 Nov 4;16:17588359241289517. eCollection 2024. PMID: 39502404
- Leone AG, Mai AS, Fong KY, Yap DWT, Kato K, Smyth E, Moehler M, Seong JTC, Sundar R, Zhao JJ, **Pietrantonio F**. [Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups](#). *ESMO Open*. 2024 Nov;9(11):103962. Epub 2024 Oct 18. PMID: 39426081
- Margalit O, Stemmer A, Chapin WJ, Shacham-Shmueli E, Kopetz S, Andre T, Overman MJ, **Pietrantonio F**, Boursi B. [Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients](#). *Eur J Cancer*. 2024 Nov;212:114336. Epub 2024 Sep 20. PMID: 39316932
- Tosi F, Salvatore L, Tamburini E, Artale S, Lonardi S, Marchetti S, Pastorino A, **Pietrantonio F**, Puccini A, Rojas-Llimpe FL, Vincenzi B, Mariano S, Negri F, Bencardino K, Pinto C, Aschele C, Siena S. [Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study](#). *ESMO Open*. 2024 Oct;9(10):103929. Epub 2024 Oct 1. PMID: 39357124
- Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, **Pietrantonio F**, Lonardi S, Gallois C, Taieb J. [BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer](#). *Eur J Cancer*. 2024 Oct;210:114290. Epub 2024 Aug 22. PMID: 39216175
- Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, **Pietrantonio F**, Pusceddu S. [Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial](#). *Eur J Cancer*. 2024 Sep;209:114276. Epub 2024 Aug 9. PMID: 39128186
- Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, **Pietrantonio F**, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. [Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer \(DESTINY-CRC02\): primary results from a multicentre, randomised, phase 2 trial](#). *Lancet Oncol*. 2024 Sep;25(9):1147-1162. Epub 2024 Aug 5. PMID: 39116902
- **Pietrantonio F**, Serreghi A, Zerbe H, Svenningsson P, Aigner L. [The leukotriene receptor antagonist montelukast as a potential therapeutic adjuvant in multiple sclerosis - a review](#). *Front Pharmacol*. 2024 Sep 13;15:1450493. eCollection 2024. PMID: 39346564
- Platt JR, Allotey J, Alouani E, Glasbey J, Intini R, Lonardi S, Mazzoli G, Militello AM, Modest DP, Palle J, **Pietrantonio F**, Riyadh K, Samuel L, Schulze AV, Shiu KK, Taieb J, Tolan DJM, West NP, Westwood AC, Williams CJM, Seligmann JF. [Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series](#). *ESMO Open*. 2024 Sep;9(9):103698. Epub 2024 Sep 5. PMID: 39241497
- Ciardiello D, Boscolo Bielo L, Napolitano S, Martinelli E, Troiani T, Nicastro A, Latiano TP, Parente P, Maiello E, Avallone A, Normanno N, Pisconti S, Nisi C, Bordonaro R, Russo AE, Tamburini E, Toma I, Lotesoriere C, Vallarelli S, Zampino MG, Fazio N, Curigliano G, De Vita F, Ciardiello F, Martini G; CAPRI-2 GOIM study group. [Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic](#)

- [colorectal cancer in the CAPRI 2-GOIM trial](#). Ann Oncol. 2024 Aug 29:S0923-7534(24)03914-0. Online ahead of print. PMID: 39214459
- Antoniotti C, Rossini D, **Pietrantonio F**, Salvatore L, Lonardi S, Tamperi S, Marmorino F, Moretto R, Prisciandaro M, Tamburini E, Tortora G, Passardi A, Bergamo F, Raimondi A, Ritorto G, Borelli B, Conca V, Ugolini C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Boni L, Galon J, Cremolini C. [Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study](#). J Clin Oncol. 2024 Aug 1;42(22):2637-2644. Epub 2024 Jun 12. PMID: 38865678
 - Bodalal Z, Hong EK, Trebeschi S, Kurilova I, Landolfi F, Bogveradze N, Castagnoli F, Randon G, Snaebjornsson P, **Pietrantonio F**, Lee JM, Beets G, Beets-Tan R. [Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study](#). Eur Radiol Exp. 2024 Aug 26;8(1):98. PMID: 39186200
 - Margonis GA, Wang JJ, Boerner T, Moretto R, Buettner S, Andreatos N, Gagnière J, Wagner D, Løes IM, Bergamo F, **Pietrantonio F**, Scartozzi M, Spallanzani A, Vincenzi B, Antoniou E, Pikoulis E, Sartore-Bianchi A, Stasinou S, Sasaki K, Pawlik TM, Orlandi A, Pella N, Fitschek F, Kaczirek K, Dupré A, Pozios I, Beyer K, Kornprat P, Aucejo FN, Burkhart R, Weiss MJ, Lønning PE, Poultides G, Cremolini C, Kreis ME, D'Angelica M. [Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study](#). Br J Surg. 2024 Jul 2;111(7):znae176. PMID: 39051667
 - Martinelli E, Ciardiello D, Martini G, Napolitano S, Del Tufo S, D'Ambrosio L, De Chiara M, Famiglietti V, Nacca V, Cardone C, Avallone A, Cremolini C, **Pietrantonio F**, Maiello E, Granata V, Troiani T, Cappabianca S, Ciardiello F, Nardone V, Reginelli A. [Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial](#). Clin Drug Investig. 2024 Jul;44(7):541-548. Epub 2024 Jun 17. PMID: 38886336
 - Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, **Pietrantonio F**. [Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer](#). Ann Oncol. 2024 Jul;35(7):643-655. Epub 2024 May 22. PMID: 38777726
 - Martinelli E, Ciardiello D, Martini G, Napolitano S, Del Tufo S, D'Ambrosio L, De Chiara M, Famiglietti V, Nacca V, Cardone C, Avallone A, Cremolini C, **Pietrantonio F**, Maiello E, Granata V, Troiani T, Cappabianca S, Ciardiello F, Nardone V, Reginelli A. [Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial](#). Clin Drug Investig. 2024 Jul;44(7):541-548. Epub 2024 Jun 17. PMID: 38886336
 - Marinelli D, Sabatini A, Bengala E, Ciurluini F, Picone V, Santini D, **Pietrantonio F**, Rossini D, Cremolini C. [Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer-single versus double checkpoint inhibition](#). ESMO Open. 2024 Jun;9(6):103483. Epub 2024 Jun 3. PMID: 38833965
 - Antoniotti C, Rossini D, **Pietrantonio F**, Salvatore L, Lonardi S, Tamperi S, Marmorino F, Moretto R, Prisciandaro M, Tamburini E, Tortora G, Passardi A, Bergamo F, Raimondi A, Ritorto G, Borelli B, Conca V, Ugolini C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Boni L, Galon J, Cremolini C. [Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study](#). J Clin Oncol. 2024 Jun 12:JCO2302728.. Online ahead of print. PMID: 38865678
 - Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamperi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, **Pietrantonio F**, de Braud F, Mazzaferro V. Correction to: [A phase II/III randomized clinical trial of CisPlatin pLUs Gemcitabine and Nabpaclitaxel \(GAP\) as pReoperative chemotherapy versus immediate resection in patients with resectable Biliary tract cancers \(BTC\) at high risk for recurrence: PURITY study](#). BMC Cancer. 2024 May 6;24(1):563. PMID: 38711003
 - Sorrentino L, Daveri E, Belli F, Vigorito R, Battaglia L, Sabella G, Patti F, Randon G, **Pietrantonio F**, Vernieri C, Scaramuzza D, Villa S, Milione M, Gronchi A, Cosimelli M, Guaglio M. [Management of patients with locally recurrent rectal cancer with a previous history of distant metastases: retrospective cohort study](#). BJS Open. 2024 May 8;8(3):zrae061. PMID: 38869237
 - Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, **Pietrantonio F**. [Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials](#). Eur J Cancer. 2024 May;203:114043. Epub 2024 Apr 4. PMID: 38598921
 - Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G, Napolitano S, Famiglietti V, Del Tufo S, Masi G, Santini D, Avallone A, **Pietrantonio F**, Lonardi S, Di Maio M, Zampino MG, Fazio N, Bardelli A, Siena S, Cremolini C, Sartore-Bianchi A, Ciardiello F. [Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial](#). JAMA Netw Open. 2024 Apr 1;7(4):e245635. PMID: 38592721
 - Germani MM, Vetere G, Santamaria F, Intini R, Ghelardi F, Bensi M, Boccaccino A, Minelli A, Carullo M, Ciraci P, Passardi A, Santucci S, Giampieri R, Persano M, Fenocchio E, Puccini A, Lonardi S, **Pietrantonio F**, Salvatore L, Cremolini C. [Treatment of](#)

- patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open. 2024 Apr;9(4):102996. Epub 2024 Apr 12. PMID: 38613911
- Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncol. 2024 Apr 21;63:213-219. PMID: 38647024
 - Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamperi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, **Pietrantonio F**, de Braud F, Mazzaferro V. A phase II/III randomized clinical trial of CisPlatin plus Gemcitabine and Nabpaclitaxel (GAP) as preoperative chemotherapy versus immediate resection in patients with resectable Biliary Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer. 2024 Apr 8;24(1):436 PMID: 38589856
 - Petrelli F, Antista M, Marra F, Cribiu' FM, Rampulla V, **Pietrantonio F**, Dottorini L, Ghidini M, Luciani A, Zaniboni A, Tomasello G. Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024 Feb 29;16:17588359241231259. eCollection 2024. PMID: 38435432
 - Germani MM, Vetere G, Giordano M, Ciraci P, Capone I, Tamborini E, Conca E, Busico A, **Pietrantonio F**, Piva VM, Boccaccino A, Simionato F, Bortolot M, Manca P, Lonardi S, Conca V, Borelli B, Carullo M, Del Re M, Fontanini G, Rossini D, Cremolini C. Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial. Front Oncol. 2024 Feb 9;13:1307545. PMID: 38406172
 - Berardi R, Rossi F, Papa R, Appetecchia M, Baggio G, Bianchini M, Mazzei T, Maria Moretti A, Ortona E, **Pietrantonio F**, Tarantino V, Vavalà T, Cinieri S. Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM). ESMO Open. 2024 Feb;9(2):102243. Epub 2024 Feb 23. PMID: 38394984
 - Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S, Khan K, Fontana E, Angerilli V, Delrieux M, Nava Rodrigues D, Procaccio L, Rao S, Watkins D, Starling N, Chau I, Braconi C, Fotiadis N, Begum R, Guppy N, Howell L, Valenti M, Cribbes S, Kolozsvari B, Kirkin V, Lonardi S, Ghidini M, Passalacqua R, Elghadi R, Magnani L, Pinato DJ, Di Maggio F, Ghelardi F, Sottotetti E, Vetere G, Ciraci P, Vlachogiannis G, **Pietrantonio F**, Cremolini C, Cortellini A, Loupakakis F, Fassin M, Valeri N. Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer. Clin Cancer Res. 2024 Feb 20. Online ahead of print. PMID: 38376926
 - Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, Luchini C, **Pietrantonio F**, Ugolini C, Vanoli A, Fassin M. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion. Pathol Res Pract. 2024 Feb;254:155145. Epub 2024 Jan 23. PMID: 38277741
 - **Pietrantonio F**, Rothwell D, Valpione S. Controversies in upper GI: liquid biopsies. ESMO Open. 2024 Jan;9(1):102204.. Epub 2023 Dec 19. PMID: 38118366
 - Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, Pusceddu S, Sposito C, Coppa J, Morano F, **Pietrantonio F**, Di Bartolomeo M, Mariani L, Mazzaferro V, de Braud F, Niger M. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Jan 2;7(1):e2350756. PMID: 38190183
 - Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, Luchini C, **Pietrantonio F**, Ugolini C, Vanoli A, Fassin M. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion. Pathol Res Pract. 2024 Jan 23;254:155145. Online ahead of print. PMID: 38277741
 - Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, **Pietrantonio F**. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clin Cancer Res. 2024 Jan 17;30(2):436-443. PMID: 37610454
 - Lonardi S, **Pietrantonio F**. New options for late-line treatment of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2024 Feb;21(2):76-77. PMID: 38066100
 - Puliga E, De Bellis C, Vietti Michelina S, Capeloa T, Migliore C, Orrù C, Baiocchi GL, De Manzoni G, **Pietrantonio F**, Reddavid R, Fumagalli Romario U, Ambrogio C, Corso S, Giordano S. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models. Gastric Cancer. 2024 Jan 23. Online ahead of print. PMID: 38261067

2023:

- **Pietrantonio F**, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antonioti C, Ambrosini M, Piva VM, Nichetti F, Fassin M, Cremolini C, Lonardi S. Negative

- [hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFFOX or 5-FU/LV. Eur J Cancer. 2023 Oct 20;195:113396. Online ahead of print. PMID: 37924647](#)
- Leone AG, Casolino R, Trapani D, Miceli R, Massagrande M, Morano F, La Verde N, Dalu D, Berardi R, Marsoni S, Lambertini M, Iula B, Carieri E, Converti M, Di Maio M, Beretta GD, Perrone F, **Pietrantonio F**, Cinieri S; Italian Foundation of Medical Oncology (Fondazione AIOM); Italian Association of Medical Oncology (AIOM). [Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations. EClinicalMedicine. 2023 Oct 17;65:102277. eCollection 2023 Nov. PMID: 37877000](#)
 - Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, **Pietrantonio F**. [Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Oct 22. Online ahead of print. PMID: 37870968](#)
 - Moretto R, Germani MM, Ros J, Daniel F, Ghelardi F, Vetere G, Giordano M, Toledo RA, Bergamo F, Randon G, Elez E, Lonardi S, **Pietrantonio F**, Vignali P, Rossini D, Matito J, Ugolini C, Fontanini G, Masi G, Cremolini C. [Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy JCO Precis Oncol. 2023 Sep;7:e2300255. PMID: 37797285](#)
 - Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, Valli I, Frassinetti GL, Passardi A, Di Bartolomeo M, Pietrantonio F, Gelsomino F, Carandina I, Banzi M, Martella L, Bonetti AV, Boccaccino A, Molinari C, Marisi G, Ugolini G, Nanni O, Tamberi S. [Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. ESMO Open. 2023 Oct;8\(5\):101824. Epub 2023 Sep 27. PMID: 37774508](#)
 - Tang TY, Nichetti F, Kaplan B, Lonardi S, **Pietrantonio F**, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M. [Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 Sep 29. Online ahead of print. PMID: 37773629](#)
 - Pretta A, Ziranu P, Giampieri R, Pinna G, Randon G, Donisi C, Ravarino A, Loi F, Deias G, Palmas E, Pretta G, Morano F, Semonella F, Mariani S, Deidda MA, Pusceddu V, Puzzone M, Lai E, Solinas C, Restivo A, Zorcolo L, Barbara R, Berardi R, Faa G, **Pietrantonio F**, Scartozzi M. [Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy. Br J Cancer. 2023 Nov;129\(10\):1619-1624. Epub 2023 Sep 25. PMID: 37749283](#)
 - Morano F, **Pietrantonio F**. [Anti-Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer-Another Piece to the Puzzle. JAMA Netw Open. 2023 Sep 5;6\(9\):e2333488. PMID: 37721757](#)
 - André T, **Pietrantonio F**, Avallone A, Gumus M, Wyrwicz L, Kim JG, Yalcin S, Kwiatkowski M, Lonardi S, Zolnierok J, Odeleye-Ajakaye A, Leconte P, Fogelman D, Kim TW. [KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. Future Oncol. 2023 Sep 13. Online ahead of print. PMID: 37701986.](#)
 - Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, Kurreck A, Meade AM, Díaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhäuser G, Fisher D, Morano F, **Pietrantonio F**, Modest DP. [Optimal maintenance strategy following FOLFFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. Eur J Cancer. 2023 Sep;190:112945. Epub 2023 Jun 19. PMID: 37441940](#)
 - Margonis GA, Boerner T, Bachet JB, Buettner S, Moretto R, Andreatos N, Sartore-Bianchi A, Wang J, Kamphues C, Gagniere J, Lonardi S, Løes IM, Wagner D, Spallanzani A, Sasaki K, Burkhart R, **Pietrantonio F**, Pikoulis E, Pawlik TM, Truant S, Orlandi A, Pikouli A, Pella N, Beyer K, Poultsides G, Seeliger H, Aucejo FN, Kornprat P, Kaczirek K, Lønning PE, Kreis ME, Wolfgang CL, Weiss MJ, Cremolini C, Benoist S, D'Angelica M. [Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions. Ann Surg. 2023 Sep 1;278\(3\):e540-e548 Epub 2022 Dec 1. PMID: 36453261](#)
 - Colle R, Lonardi S, Cachanado M, Overman MJ, Elez E, Fakih M, Corti F, Jayachandran P, Svrcek M, Dardenne A, Cervantes B, Duval A, Cohen R, **Pietrantonio F**, André T. [BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 Sep 7;28\(9\):771-779. PMID: 37023721](#)
 - Ghelardi F, Raimondi A, Morano F, Randon G, Pannone A, Guaglio M, Mazzoli G, Nasca V, Milione M, Leoncini G, Sabella G, Greco GF, Lampis BR, Galassi M, Delfanti S, Nannini M, Intini R, Baratti D, Di Bartolomeo M, Deraco M, **Pietrantonio F**. [Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin. Clin Colorectal Cancer. 2023 Aug 11:S1533-0028\(23\)00078-6. Online ahead of print. PMID: 37657955](#)
 - Boccaccino A, Rossini D, Raimondi A, Carullo M, Lonardi S, Morano F, Santini D, Tomasello G, Niger M, Zaniboni A, Daniel F, Bustreo S, Procaccio L, Clavarezza M, Cupini S, Libertini M, Palermo F, **Pietrantonio F**, Cremolini C. [Adverse events during first-line treatments for mCRC: The Toxicity over Time \(ToxT\) analysis of three randomised trials. Eur J Cancer. 2023 Aug;189:112910. Epub 2023 May 6. PMID: 37301718](#)
 - Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, **Pietrantonio F**; GONO Foundation Investigators. [Initial Panitumumab Plus Fluorouracil, Leucovorin,](#)

-
- [and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation.](#) J Clin Oncol. 2023 Aug 3;JCO2300506. Online ahead of print. PMID: 37535876
- Randon G, **Pietrantonio F.** [Towards multiomics-based dissection of anti-EGFR sensitivity in colorectal cancer.](#) Clin Cancer Res. 2023 Aug 18;CCR-23-1954. Online ahead of print. PMID: 37594733
 - Marmorino F, Faggioni L, Rossini D, Gabelloni M, Goddi A, Ferrer L, Conca V, Vargas J, Biagiarelli F, Daniel F, Carullo M, Vetere G, Granetto C, Boccaccio C, Cioni D, Antonuzzo L, Bergamo F, **Pietrantonio F**, Cremolini C, Neri E. [The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.](#) Future Oncol. 2023 Jul;19(23):1601-1611. PMID: 37577810
 - Manca P, Corti F, Intini R, Mazzoli G, Miceli R, Germani MM, Bergamo F, Ambrosini M, Cristarella E, Cerantola R, Boccaccio C, Ricagno G, Ghelardi F, Randon G, Leoncini G, Milione M, Fassan M, Cremolini C, Lonardi S, **Pietrantonio F.** [Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.](#) Eur J Cancer. 2023 Jul;187:15-24. Epub 2023 Mar 31. PMID: 37099945
 - Zhao JJ, **Pietrantonio F**, Sundar R. [Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma-Reply.](#) JAMA Oncol. 2023 Jul 1;9(7):1005-1006. PMID: 37166787
 - Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klemptner SJ, Maron SB, Cerantola R, Chao J, Fornaro L, Ferrari Bravo W, Ghelardi F, Ambrosini M, Manca P, Salati M, Kawazoe A, Zhu V, Cowzer D, Genovesi V, Lonardi S, Shitara K, André T, **Pietrantonio F.** [Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.](#) J Immunother Cancer. 2023 Jun;11(6):e007104. PMID: 37277193
 - Sposito C, **Pietrantonio F**, Maspero M, Di Benedetto F, Vivarelli M, Tisone G, De Carlis L, Romagnoli R, Gruttadauria S, Colledan M, Agnes S, Ettorre G, Baccarani U, Torzilli G, Di Sandro S, Pinelli D, Caccamo L, Sartore Bianchi A, Spreafico C, Torri V, Mazzaferro V. [Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial \(COLT trial\).](#) Clin Colorectal Cancer. 2023 Jun;22(2):250-255. Epub 2023 Feb 3. PMID: 36822922
 - Leone AG, Miceli R, Trapani D, Massagrande M, Morano F, Marsoni S, La Verde N, Berardi R, Casolino R, Lambertini M, Dalu D, Di Maio M, Beretta GD, Perrone F, Cinieri S, **Pietrantonio F.** [Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology.](#) ESMO Open. 2023 Jun;8(3):101578. Epub 2023 Jun 2. PMID: 37270870
 - Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martín Á, Antista M, Toledo R, Martinelli E, **Pietrantonio F**, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. [Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.](#) Ann Oncol. 2023 Jun;34(6):543-552. Epub 2023 Mar 14. PMID: 36921693
 - Castagnoli L, Corso S, Franceschini A, Raimondi A, Bellomo SE, Dugo M, Morano F, Prisciandaro M, Brich S, Belfiore A, Vingiani A, Di Bartolomeo M, Pruner G, Tagliabue E, Giordano S, **Pietrantonio F**, Pupa SM. [Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.](#) Cell Oncol (Dordr). 2023 Jun;46(3):661-676. PMID: 36753044
 - Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, **Pietrantonio F**, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Morano F, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C. [An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.](#) Clin Cancer Res. 2023 Jun 13;29(12):2291-2298. PMID: 37022350
 - Fornaro L, Lonardi S, Catanese S, Nappo F, **Pietrantonio F**, Pellino A, Angerilli V, Signorini F, Salani F, Murgioni S, Neculaescu IA, Bruno R, Vivaldi C, Ricagno G, Masi G, Bergamo F, Ugolini C, Fassan M. [Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.](#) Gastric Cancer. 2023 Jun 29. Online ahead of print. PMID: 37382783
 - Petrelli A, Rizzolio S, **Pietrantonio F**, Bellomo SE, Benelli M, De Cecco L, Romagnoli D, Berrino E, Orrù C, Ribisi S, Moya-Rull D, Migliore C, Conticelli D, Maina IM, Puliga E, Serra V, Pellegrino B, Llop-Guevara A, Musolino A, Siena S, Sartore-Bianchi A, Prisciandaro M, Morano F, Antista M, Fumagalli U, De Manzoni G, Degiuli M, Baiocchi GL, Amisano MF, Ferrero A, Marchiò C, Corso S, Giordano S. [BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.](#) Cancer Res. 2023 May 15;83(10):1699-1710. PMID: 37129948
 - Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, **Pietrantonio F**, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanen A. [Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.](#) Gastric Cancer. 2023 May;26(3):425-437. Epub 2023 Mar 7. PMID: 36881202
 - Bersani F, Picca F, Morena D, Righi L, Napoli F, Russo M, Oddo D, Rospo G, Negrino C, Castella B, Volante M, Listì A, Zambelli V, Benso F, Tabbò F, Bironzo P, Monteleone E, Poli V, **Pietrantonio F**, Di Nicolantonio F, Bardelli A, Ponzetto C, Novello S, Scagliotti

- GV, Taulli R. [Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.](#) J Exp Clin Cancer Res. 2023 May 12;42(1):120. PMID: 37170152
- Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, Ugolini C, Proietti A, Conca V, Kassambara A, **Pietrantonio F**, Salvatore L, Lonardi S, Tamberi S, Tamburini E, Poma AM, Fieschi J, Fontanini G, Masi G, Galon J, Cremolini C. [Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.](#) J Immunother Cancer. 2023 Apr;11(4):e006633. PMID: 37085190
 - Ciardiello D, Napolitano S, Famiglietti V, Esposito L, De Falco V, Di Liello A, Avallone A, Maiello E, **Pietrantonio F**, Cremolini C, Zampino MG, Fazio N, Troiani T, Martinelli E, Ciardiello F, Martini G. [Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.](#) Cancers (Basel). 2023 Apr 1;15(7):2117. PMID: 37046778
 - Leone AG, Trapani D, Schabath MB, Safer JD, Scout NFN, Lambertini M, Berardi R, Marsoni S, Perrone F, Cinieri S, Miceli R, Morano F, **Pietrantonio F**. [Cancer in Transgender and Gender-Diverse Persons: A Review.](#) JAMA Oncol. 2023 Apr 1;9(4):556-563 PMID: 36757703
 - Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, Napolitano S, Esposito L, Latiano TP, Maiello E, Del Re M, Lonardi S, Aprile G, Santini D, Masi G, Avallone A, Normanno N, **Pietrantonio F**, Pinto C, Ciardiello F, Cremolini C, Martinelli E. [Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.](#) Cancer Med. 2023 Apr;12(8):9392-9400. Epub 2023 Mar 7. PMID: 36880426
 - Moretto R, Germani MM, Giordano M, Conca V, Proietti A, Niccoli C, **Pietrantonio F**, Lonardi S, Tamburini E, Zaniboni A, Passardi A, Latiano TP, Fanotto V, Di Donato S, Prisciandaro M, Bergamo F, Masi G, Fontanini G, Ugolini C, Cremolini C. [Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.](#) Br J Cancer. 2023 Mar;128(7):1391-1399. PMID: 36759721 Clinical Trial.
 - Prete AA, Manca P, Messina M, Formica V, Frassinetti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, **Pietrantonio F**, Lonardi S. [Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study.](#) Eur J Cancer. 2023 Mar;182:87-97. Epub 2023 Jan 9. PMID: 36753836
 - **Pietrantonio F**, Manca P, Bellomo SE, Corso S, Raimondi A, Berrino E, Morano F, Migliore C, Niger M, Castagnoli L, Pupa SM, Marchiò C, Di Bartolomeo M, Restuccia E, Lambertini C, Tabernero J, Giordano S. [HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.](#) Clin Cancer Res. 2023 Feb 1;29(3):571-580. PMID: 36413222
 - Yap DWT, Leone AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, **Pietrantonio F**. [Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.](#) JAMA Oncol. 2023 Feb 1;9(2):215-224. PMID: 36480211
 - Maspero M, Sposito C, Viridis M, Citterio D, **Pietrantonio F**, Bhoori S, Belli F, Mazzaferro V. [Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.](#) Cancers (Basel). 2023 Jan 5;15(2):345.. PMID: 36672295
 - D'Angelo A, Kilili H, Chapman R, Generali D, Tinhofer I, Luminari S, Donati B, Ciarrocchi A, Giannini R, Moretto R, Cremolini C, **Pietrantonio F**, Sobhani N, Bonazza D, Prins R, Song SG, Jeon YK, Pisignano G, Cinelli M, Bagby S, Urrutia AO. [Immune-related pancreatic gene expression signatures of patient survival revealed by NanoString-based analyses](#) PLoS One. 2023 Jan 17;18(1):e0280364.. eCollection 2023. PMID: 36649303
 - Borelli B, Crucitta S, Boccaccino A, Antista M, Antoniotti C, Marmorino F, Rossini D, Conca V, Germani MM, Provenzano L, Spagnoletti A, Leone AG, Cucchiara F, **Pietrantonio F**, Del Re M, Danesi R, Masi G, Cremolini C, Moretto R. [TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.](#) Tumori. 2023 Jan 6:3008916221147944.. Online ahead of print. PMID: 36609197
 - Gallois C, Landi M, Taieb J, Sroussi M, Saberzadeh-Ardestani B, Cazelles A, Lonardi S, Bergamo F, Intini R, Maddalena G, **Pietrantonio F**, Corti F, Ambrosini M, Martinetti A, Germani MM, Boccaccio C, Vetere G, Mouillet-Richard S, de Reynies A, Sinicrope FA, Cremolini C, Laurent-Puig P. [Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.](#) Clin Cancer Res. 2023 Jul 13:CCR-22-3964. Online ahead of print. PMID: 37439810
 - Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, **Pietrantonio F**. [Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.](#) J Immunother Cancer. 2023 Jan;11(1):e005493. PMID: 36593068
 - Baratti D, Kusamura S, Guaglio M, Milione M, **Pietrantonio F**, Cavalleri T, Morano F, Deraco M. [Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and Outcomes.](#) Ann Surg Oncol. 2023 Jan;30(1):404-414. Epub 2022 Sep 12. PMID: 36094689

2022:

- Dell'Aquila E, Rossini D, Fulgenzi CAM, Passardi A, Tamburini E, Vetere G, Carullo M, Citarella F, Antoniotti C, Zaniboni A, **Pietrantonio F**, Spagnoletti A, Marmorino F, Borelli B, Allegrini G, Lonardi S, Nappo F, Masi G, Cremolini C, Santini D Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials. ESMO Open. 2022 Dec;7(6):100606. Epub 2022 Oct 31. PMID: 36327757
- Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V, Xiu J, Stafford P, Oberley M, Abraham J, Spetzler D, Rossini D, Antoniotti C, Marshall J, Shields A, Lopes G, Lonardi S, **Pietrantonio F**, Tomasello G, Passardi A, Tamburini E, Santini D, Aprile G, Masi G, Falcone A, Lenz HJ, Korn M, Cremolini C. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. J Natl Cancer Inst. 2022;114:271-279. PMID: 34469533
- Marmorino F, Prisciandaro M, Giordano M, Ortolan E, Crucitta S, Manca P, Antoniotti C, Valenti MM, Danesi R, Conca V, Mazzoli G, Boccaccino A, Carullo M, Martinetti A, Sottotetti E, Masi G, Sposito C, Zaffaroni N, Milione M, Fontanini G, Del Re M, **Pietrantonio F**, Cremolini C. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases. JCO Precis Oncol. 2022 Nov;6:e2200244. PMID: 36356286
- Moretto R, Elliott A, Rossini D, Intini R, Conca V, **Pietrantonio F**, Sartore-Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, Cremolini C Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? Br J Cancer. 2022 Sep;127(5):957-967. PMID: 35665778
- Raimondi A, Randon G, Prisciandaro M, Pagani F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore-Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Petrelli F, Antonuzzo L, Giordano M, Rossi A, Di Bartolomeo M, Di Maio M, **Pietrantonio F**, Morano F. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. Int J Cancer. 2022 Nov 15;151(10):1760-1769. PMID: 35678328
- Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, **Pietrantonio F**, Dienstmann R, Tabernero J, Toledo RA. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170. PMID: 3609721
- Crisafulli G, Sartore-Bianchi A, Lazzari L, **Pietrantonio F**, Amatu A, Macagno M, Barault L, Cassingena A, Bartolini A, Luraghi P, Mauri G, Battuello P, Personeni N, Zampino MG, Pessei V, Vitiello PP, Tosi F, Idotta L, Morano F, Valtorta E, Bonoldi E, Germano G, Di Nicolantonio F, Marsoni S, Siena S, Bardelli A. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discov 2022;12:1656-1675. PMID: 35522273
- Sartore-Bianchi A, **Pietrantonio F**, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med 2022; 28:1612-1618. PMID: 35915157
- Mazzoli G, Cohen R, Lonardi S, Corti F, Elez E, Fakih M, Jayachandran P, Colle R, Shah AT, Salati M, Fenocchio E, Salvatore L, Ambrosini M, Ros J, Intini R, Cremolini C, Overman MJ, André T, **Pietrantonio F**. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022 Sep;172:171-181. PMID: 35777274
- Morano F, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, Murgioni S, Randon G, Palermo F, Antonuzzo L, Pella N, Racca P, Prisciandaro M, Niger M, Corti F, Bergamo F, Zaniboni A, Ratti M, Palazzo M, Cagnazzo C, Calegari MA, Marmorino F, Capone I, Conca E, Busico A, Brich S, Tamborini E, Perrone F, Di Maio M, Milione M, Di Bartolomeo M, de Braud F, **Pietrantonio F**. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. J Clin Oncol. 2022; 40:1562-1573. PMID: 35258987
- Niger M, Nichetti F, Casadei-Gardini A, Rizzato MD, Pircher C, Bini M, Franza A, Rimini M, Burgio V, Sposetti C, Fornaro L, Rapposelli IG, D'Amico FE, Aprile G, Vivaldi C, Frassinetti GL, Milione M, Leoncini G, Cappetta A, Vasile E, Fassan M, Morano F, Perrone F, Tamborini E, Pruner G, Lonardi S, Mazzaferro V, **Pietrantonio F**, Di Bartolomeo M, de Braud F. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study. Int J Cancer. 2022 Oct 15;151(8):1310-1320. PMID: 35723131
- Rossini D, Germani MM, Lonardi S, **Pietrantonio F**, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, Randon G, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022 Jul;170:64-72. PMID: 35594613

- Ciardiello D, Famiglietti V, Napolitano S, Esposito L, **Pietrantonio F**, Avallone A, Maiello E, Cremolini C, Troiani T, Martinelli E, Ciardiello F, Martini G. [Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.](#) Clin Colorectal Cancer. 2022 Jun;21(2):141-148. PMID: 35101346
- Rossini D, Antoniotti C, Lonardi S, **Pietrantonio F**, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. [Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.](#) J Clin Oncol. 2022; 40:2878-2888 PMID: 35666229
- Antoniotti C, Rossini D, **Pietrantonio F**, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopoulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. [Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer \(AtezoTRIBE\): a multicentre, open-label, randomised, controlled, phase 2 trial.](#) Lancet Oncol. 2022; 23:876-887.PMID: 35636444
- Maron SB, Moya S, Morano F, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, Yoshino T, Shitara K, Nakamura Y, Saeed A, Kasi PM, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, **Pietrantonio F**, Klempner SJ, Catenacci DVT. [Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.](#) J Clin Oncol. 2022; 40:2458-2467. PMID: 35349370
- Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hülle J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, **Pietrantonio F**, Di Bartolomeo M, de Braud F. [MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.](#) Mol Oncol. 2022 Jul;16(14):2733-2746. PMID: 35621918
- Manca P, Corallo S, Lonardi S, Fucà G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smiroldo V, Ratti M, Murialdo R, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, Morano F, **Pietrantonio F**. [Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.](#) Br J Cancer. 2022; 126:449-455. PMID: 34811502
- Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, **Pietrantonio F**. [ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.](#) JCO Precis Oncol. 2022; 6:e2200015. PMID: 35476549
- Antoniotti C, Germani MM, Rossini D, Lonardi S, **Pietrantonio F**, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C. [FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.](#) Eur J Cancer. 2022 May;167:23-31. PMID: 35366570
- Antoniotti C, Marmorino F, Boccaccino A, Martini S, Antista M, Rossini D, Zuco V, Prisciandaro M, Conca V, Zucchelli G, Borelli B, Cosentino P, Germani MM, Bosco MF, Carullo M, Vetere G, Moretto R, Giordano M, Masi G, **Pietrantonio F**, Zaffaroni N, Cremolini C. [Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.](#) Eur J Cancer. 2022 Apr;165:116-124. PMID: 35231767
- Randon G, Maddalena G, Germani MM, Pircher CC, Manca P, Bergamo F, Giordano M, Sposetti C, Montagna A, Vetere G, Zambelli L, Rasola C, Boccaccino A, Pagani F, Ambrosini M, Massafra M, Fontanini G, Milione M, Fassan M, Cremolini C, Lonardi S, **Pietrantonio F**. [Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.](#) JCO Precis Oncol. 2022 ;6:e2200037.PMID: 35544729
- Fucà G, Raimondi A, Prisciandaro M, Lonardi S, Cremolini C, Ratti M, Clavarezza M, Murialdo R, Sartore-Bianchi A, Smiroldo V, Berenato R, Racca P, Bergamo F, Corallo S, Di Bartolomeo M, de Braud F, Morano F, **Pietrantonio F**. [Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.](#) Oncologist. 2022 Feb 3;27(1):e29-e36. PMID: 35305093
- Niger M, Nichetti F, Dell'Angelo F, Cappelletti V, Pircher C, Vismara M, Cotsoglou C, Bhoori S, Vingiani A, Di Bartolomeo M, **Pietrantonio F**, de Braud F, Pruneri G, Daidone MG, Mazzaferro V. [Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma](#) JCO Precis Oncol. 2022 Mar;6:e2100472. PMID: 35319965

- Angerilli V, Sabella G, Centonze G, Lonardi S, Bergamo F, Mangogna A, **Pietrantonio F**, Fassan M, Milione M. [BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications](#). Crit Rev Oncol Hematol. 2022 Apr;172:103647. PMID: 35248712
- Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, **Pietrantonio F**, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C. [Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature](#) Cancer Treat Rev. 2022 Feb;103:102326. PMID: 35016085
- Leone AG, Petrelli F, Ghidini A, Raimondi A, Smyth EC, **Pietrantonio F** [Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score](#). ESMO Open. 2022 Feb;7(1):100380. Epub 2022 Jan 27. PMID: 35093742
- Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fasso M, Niger M, **Pietrantonio F**, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P. [Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition](#). Gut. 2022;71:1277-1288 PMID: 34433583
- Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, **Pietrantonio F**. [Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers](#). J Immunother Cancer. 2022 Feb;10(2):e004001. PMID: 35110358
- Randon G, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, Manca P, Bergamo F, Pagani F, Antista M, Angerilli V, Ros Montaña FJ, Lavacchi D, Boccaccino A, Fucà G, Brich S, Cattaneo L, Fassan M, **Pietrantonio F**, Lonardi S. [Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer](#). Eur J Cancer. 2022;161:90-98. PMID: 34933155

2021:

- Puliga E, Corso S, **Pietrantonio F**, Giordano S [Microsatellite instability in Gastric Cancer: Between lights and shadows](#). Cancer Treat Rev. 2021;95:102175. PMID: 33721595
- Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, Morano F, Cremolini C, **Pietrantonio F**. [EGFR Amplification in Metastatic Colorectal Cancer](#). J Natl Cancer Inst. 2021;113: 1561-1569 PMID: 33825902
- Corso S, **Pietrantonio F**, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, De Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, Morano F, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S. [Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas](#). Clin Cancer Res. 2021; 27:3126-3140 PMID: 33542076
- Rossini D, Boccaccino A, Sbrana A, Daniel F, Borelli B, Raimondi A, Santini D, Conca V, Tomasello G, Caponnetto S, Marmorino F, Zaniboni A, Buonadonna A, Masi G, Lonardi S, **Pietrantonio F**, Falcone A, Antonuzzo A, Cremolini C. [Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO](#). ESMO Open. 2021 Dec;6(6):100293. Epub 2021 Oct 22. PMID: 34689001
- Ciardiello D, Famiglietti V, Napolitano S, Esposito L, Normanno N, Avallone A, Latiano T, Maiello E, **Pietrantonio F**, Cremolini C, Santabarbara G, Pinto C, Troiani T, Martinelli E, Ciardiello F, Martini G. [Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab \(CAVE\) as Rechallenge Strategy](#). Cancers (Basel). 2021 Nov 15;13(22):5715. PMID: 34830870
- Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, Orciuolo C, Frassinetti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, **Pietrantonio F**. [Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study](#). J Immunother Cancer. 2021 Nov;9(11):e002996. PMID: 34815354
- Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V, Amatu A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Corallo S, Morano F, Di Bartolomeo M, Di Maio M, **Pietrantonio F**. [Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study](#). ESMO Open. 2021 Oct;6(5):100246. Epub 2021 Aug 17. PMID: 3441646

- Manca P, Corallo S, Busico A, Lonardi S, Corti F, Antoniotti C, Procaccio L, Clavarezza M, Smirolto V, Tomasello G, Murialdo R, Sartore-Bianchi A, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Palermo F, Perrone F, Tamborini E, Prisciandaro M, Raimondi A, Di Bartolomeo M, Morano F, **Pietrantonio F**. [The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer](#). Clin Cancer Res. 2021; 27: 2505-2514. PMID: 33547199
- Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, **Pietrantonio F**, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, Morano F, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, Ciardiello F. [Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial](#). JAMA Oncol. 2021;7:1529-1535. PMID: 34382998
- Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, **Pietrantonio F**, Routy B, André F, Pasolli E, Delaloge S, Zitvogel L. [Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment](#). Cell Death Differ. 2021; 28:2778-2796 PMID: 33963313
- **Pietrantonio F**, Randon G, Di Bartolomeo M, Luciani A, Chao J, Smyth EC, Petrelli F. [Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials](#). ESMO Open. 2021; 100036. PMID: 33460964
- **Pietrantonio F**, Fucà G, Manca P, Pagani F, Raimondi A, Prisciandaro M, Randon G, Corti F, de Braud F, Cremolini C, Miceli R. [Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial](#). Tumori. 2021 Aug;107(4):353-359. PMID: 33021466
- Milito P, Sorrentino L, **Pietrantonio F**, Di Russo A, Citterio D, Mazzaferro V, Cosimelli M. [No benefit after neoadjuvant chemoradiation in stage IV rectal cancer: A propensity score-matched analysis on a real-world population](#). Dig Liver Dis. 2021 Aug;53(8):1041-1047. PMID: 33487580
- Moretto R, Giordano M, Poma AM, Passardi A, Boccaccino A, **Pietrantonio F**, Tomasello G, Aprile G, Lonardi S, Conca V, Granetto C, Frassoldati A, Clavarezza M, Bertolini AS, Germani MM, Ugolini C, Fontanini G, Masi G, Falcone A, Cremolini C. [Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study](#). Eur J Cancer. 2021 Aug;153:16-26. PMID: 34126333
- Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, **Pietrantonio F**, Morano F. [Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study](#). Support Care Cancer. 2021 Jul;29(7):3971-3980. PMID: 33392769
- Baratti D, Kusamura S, Niger M, Perrone F, Milione M, Cattaneo L, Guaglio M, Bartolini V, **Pietrantonio F**, Deraco M. [Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases](#). Ann Surg Oncol. 2021 Jun;28(6):3332-3342. PMID: 32974694
- **Pietrantonio F**, Fucà G, Rossini D, Schmoll HJ, Bendell JC, Morano F, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C. [FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis](#). Oncologist. 2021 Apr;26(4):302-309. PMID: 33336844
- Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, Morano F, Spallanzani A, Ambrosini M, Curigliano G, de Braud F, Zagonel V, Fucà G, **Pietrantonio F**. [The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors](#). Eur J Cancer. 2021 Jun;150:155-167. PMID: 33901794
- Fucà G, Corti F, **Pietrantonio F**. [Author response to Colle et al](#). J Immunother Cancer. 2021 Jun;9(6):e003138. PMID: 34162717
- Ughetto S, Migliore C, **Pietrantonio F**, Apicella M, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Rizzolio S, Capelôa T, Ribisi S, Degiuli M, Reddavid R, Rapa I, Fumagalli U, De Pascale S, Ribero D, Baronchelli C, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Manenti S, Bencivenga M, Sacco M, Castelli C, Siena S, Sartore-Bianchi A, Tosi F, Morano F, Raimondi A, Prisciandaro M, Gloghini A, Marsoni S, Sottile A, Sarotto I, Sapino A, Marchiò C, Cassoni P, Guarrera S, Corso S, Giordano S. [Personalized therapeutic strategies in HER2-driven gastric cancer](#). Gastric Cancer. 2021; 24:897-912. PMID: 33755862
- Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listi A, Loupakis F, Pagni F, **Pietrantonio F**, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. [RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients](#). Eur J Cancer. 2021 Mar;146:74-83. PMID: 33588147
- Fassan M, Milione M, Maddalena G, Cremolini C, Schirripa M, **Pietrantonio F**, Pella N, Dell'Aquila E, Sperti E, Zichi C, Bergamo F, Volante M, Boccaccino A, Morano F, Cortiula F, De Maglio G, Rimassa L, Smirolto V, Calvetti L, Aprile G, Salvatore L, Santini D, Salmaso R, Centonze G, Biason P, Borga C, Lonardi S, Zagonel V, Dei Tos AP, Di Maio M, Loupakis F. [Synaptophysin expression in](#)

V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. Eur J Cancer. 2021 Mar;146:145-154. PMID: 33607478

- Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassinetti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamperi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, **Pietrantonio F.** Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers (Basel). 2021; 7;13:2839. PMID: 34200267
- Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, Orciuolo C, Frassinetti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, **Pietrantonio F.** Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021; e002996.PMID: 34815354.
- Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, **Pietrantonio F** Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021 Apr;9(4):e002501. PMID: 33849927
- Borelli B, Fontana E, Giordano M, Antoniotti C, Lonardi S, Bergamo F, **Pietrantonio F**, Morano F, Tamburini E, Boccaccino A, Santini D, Zucchelli G, Pella N, Maiello E, Passardi A, Zaniboni A, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. ESMO Open. 2021 Apr;6(2):100073. Epub 2021 Mar 3. PMID: 33676295
- Di Cosimo S, Tagliaferri B, Generali D, Giudici F, Agustoni F, Bernardo A, Borronovo K, Farina G, Luchena G, Luciani A, Nolè F, Palmeri L, **Pietrantonio F**, Poggi G, Zucali PA, Balletti E, Catania G, Bernocchi O, D'Antonio F, Giordano M, Grossi F, Lasagna A, La Verde N, Manzoni M, Montagna B, Olgiati A, Raimondi A, Rampinelli I, Verri E, Zaniboni A, Di Maio M, Beretta G, Danova M. Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. Cancers (Basel). 2021 Mar 16;13(6):1324. PMID: 33809465
- **Pietrantonio F**, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021; 9:e003370.PMID: 34429334
- Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, Masi G, Antoniotti C, Marmorino F, Conca V, Borelli B, Martignetti A, Pecora I, Simionato F, Cupini S, Ambrosini M, Manca P, **Pietrantonio F**, Falcone A, Cremolini C. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clin Colorectal Cancer. 2021 Dec;20(4):314-317. PMID: 34364814

2020:

- Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, Zaniboni A, Tamperi S, Pressiani T, Sanna G, Cantore M, Mosconi S, Bolzoni P, Pinto C, Landi L, Soto Parra HJ, Cavanna L, Corallo S, Martinetti A, Hembrough TA, **Pietrantonio F.** Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori. 2021;107:150-159. PMID: 32522106 Clinical Trial.
- Manca P, Corallo S, Randon G, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smiroldo V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, Morano F, Pietrantonio F. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.Eur J Cancer. 2021 Feb;144:31-40. Epub 2020 Dec 13. PMID: 33321462
- Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, **Pietrantonio F**, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020; 21: 497-507.PMID: 32164906

- Moretto R, Rossini D, Zucchelli G, Lonardi S, Bergamo F, Santini D, Cupini S, Tomasello G, Caponnetto S, Zaniboni A, Antoniotti C, **Pietrantonio F**, Buonadonna A, Marmorino F, Bordonaro R, Fea E, Tamburini E, Boccaccino A, Grande R, Aprile G, Falcone A, Cremolini C. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer. 2020 Nov;139:81-89. PMID: 32979645
- Rossini D, Lonardi S, Antoniotti C, Santini D, Tomasello G, Ermacora P, Germani MM, Bergamo F, Ricci V, Caponnetto S, Moretto R, Zaniboni A, **Pietrantonio F**, Buonadonna A, Ritorto G, Masi G, Latiano TP, Rapisardi S, Falcone A, Cremolini C. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer. 2021 Jan;124(1):183-190. Epub 2020 Oct 7 PMID: 33024268
- Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, **Pietrantonio F**, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol. 2020 Oct 31;12:1758835920956862. PMID: 33193826
- Cardone C, Blauensteiner B, Moreno-Viedma V, Martini G, Simeon V, Vitiello PP, Ciardiello D, Belli V, Matrone N, Troiani T, Morgillo F, Zito Marino F, Dentice M, Nappi A, Boccaccino A, Antoniotti C, Cremolini C, **Pietrantonio F**, Prager GW, Normanno N, Maiello E, Argiles G, Elez E, Signoriello G, Franco R, Falcone A, Tabernero J, Sibilia M, Ciardiello F, Martinelli E. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2020 Oct;138:1-10. PMID: 32818762
- Schlicker A, Ellappalayam A, Beumer IJ, Snel MHJ, Mittempergher L, Diosdado B, Dreezen C, Tian S, Salazar R, Loupakis F, **Pietrantonio F**, Santos Vivas C, Martinez-Villacampa MM, Villanueva A, Sanjuán X, Schirripa M, Fassan M, Martinetti A, Fucà G, Lonardi S, Keilholz U, Glas AM, Bernards R, Vecchione L. Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. Int J Cancer. 2020 Oct 15;147(8):2303-2315. PMID: 32270478
- Rossini D, Germani MM, Pagani F, Pellino A, Dell'Aquila E, Bensi M, Liscia N, Moretto R, Boccaccino A, Prisciandaro M, Manglaviti S, Schirripa M, Vivolo R, Scartozzi M, Santini D, Salvatore L, **Pietrantonio F**, Loupakis F, Falcone A, Cremolini C. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clin Colorectal Cancer. 2020 Sep;19(3):191-199.e6. PMID: 32466976
- Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, **Pietrantonio F**, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS One. 2020 Sep 24;15(9):e0239439. PMID: 32970737
- Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, Businello G, **Pietrantonio F**, Randon G, Fucà G, Boccaccino A, Bergamo F, Lonardi S, Dei Tos AP, Fassan M, Loupakis F. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clin Colorectal Cancer. 2020 Sep;19(3):219-225. PMID: 32605718
- Dell'Aquila E, Zeppola T, Stellato M, Pantano F, Scartozzi M, Madaudo C, **Pietrantonio F**, Cremolini C, Aprile G, Vincenzi B, Moretto R, Puzzone M, Garattini SK, Lobefaro R, Tonini G, Santini D. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? Clin Med Insights Oncol. 2020 Aug 4;14:1179554920946693. PMID: 32821190
- Moretto R, Corallo S, Belfiore A, Rossini D, Boccaccino A, Lonardi S, Centonze G, Morano F, Germani MM, Loupakis F, Morelli L, Urbani L, Brich S, Marmorino F, Prisciandaro M, Aprile G, Fassan M, Cillo U, Cattaneo L, Fontanini G, De Braud F, Falcone A, Milione M, **Pietrantonio F**, Cremolini C. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. Eur J Cancer. 2020 Aug;135:78-88. PMID: 32554314
- Fontana E, Nyamundanda G, Cunningham D, Tu D, Cheang MCU, Jonker DJ, Siu LL, Sclafani F, Eason K, Ragulan C, Bali MA, Hulkki-Wilson S, Loree JM, Waring PM, Giordano M, Lawrence P, Rodrigues DN, Begum R, Shapiro JD, Price TJ, Cremolini C, Starling N, **Pietrantonio F**, Trusolino L, O'Callaghan CJ, Sadanandam A. Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. JCO Precis Oncol. 2020 Sep 29;4:PO.20.00050. PMID: 33015526
- **Pietrantonio F**, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist. 2020 Sep;25(9):803-809. PMID: 32369650
- Antoniotti C, Borelli B, Rossini D, **Pietrantonio F**, Morano F, Salvatore L, Lonardi S, Marmorino F, Tamberi S, Corallo S, Tortora G, Bergamo F, Brunella DS, Boccaccino A, Grassi E, Racca P, Tamburini E, Aprile G, Moretto R, Boni L, Falcone A, Cremolini C. AtezotriBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer. 2020 22;20 : PMID: 32698790
- Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravazza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi

- E, de Braud F, Cremolini C, **Pietrantonio F**. [The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials](#). Br J Cancer. 2020;123:403-409.PMID: 32424148.
- Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, **Pietrantonio F**, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L. [Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients](#). Eur Urol. 2020 Aug;78(2):195-206. PMID: 32376136
 - Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, **Pietrantonio F**. [Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study](#). Eur J Cancer. 2020 Aug;135:230-239. PMID: 32623288
 - **Pietrantonio F**, Fucà G, Manca P, Pagani F, Raimondi A, Prisciandaro M, Randon G, Corti F, de Braud F, Cremolini C, Miceli. [Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial](#). R. Tumori. 2021 Aug;107(4):353-359. PMID: 33021466
 - Randon G, Pagani F, **Pietrantonio F**. [MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response](#). Clin Cancer Res. 2020 Jul 1;26(13):3495. PMID: 32611628
 - Petrelli F, Ghidini M, Rausa E, Ghidini A, Cabiddu M, Borgonovo K, Ghilardi M, Parati MC, **Pietrantonio F**, Sganzerla P, Bossi AC. [Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis](#). Can J Diabetes. 2021 Mar;45(2):186-197.e2. PMID: 33039329
 - Baratti D, Kusamura S, Niger M, Perrone F, Milione M, Cattaneo L, Guaglio M, Bartolini V, **Pietrantonio F**, Deraco M. [Ann Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases](#). Surg Oncol. 2021 Jun;28(6):3332-3342. PMID: 32974694
 - Roberti MP, Yonekura S, Duong CPM, Picard M, Ferrere G, Tidjani Alou M, Rauber C, Iebba V, Lehmann CHK, Amon L, Dudziak D, Derosa L, Routy B, Flament C, Richard C, Daillère R, Fluckiger A, Van Seuningen I, Chamaillard M, Vincent A, Kourula S, Opolon P, Ly P, Pizzato E, Becharef S, Paillet J, Klein C, Marliot F, **Pietrantonio F**, Benoist S, Scoazec JY, Dartigues P, Hollebecque A, Malka D, Pagès F, Galon J, Gomperts Boneca I, Lepage P, Ryffel B, Raoult D, Eggermont A, Vanden Berghe T, Ghiringhelli F, Vandenabeele P, Kroemer G, Zitvogel L. [Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer](#). Nat Med. 2020 Jun;26(6):919-931. PMID: 32451498
 - **Pietrantonio F**, Garassino MC. [Caring for Patients With Cancer During the COVID-19 Outbreak in Italy](#). JAMA Oncol. 2020 Jun 1;6(6):821-822. PMID: 32275294
 - Petrelli F, Perego G, Ghidini A, Ghidini M, Borgonovo K, Scolari C, Nozza R, Rampulla V, Costanzo A, Varricchio A, Rausa E, **Pietrantonio F**, Zaniboni A. [A systematic review of salvage therapies in refractory metastatic colorectal cancer](#). Int J Colorectal Dis. 2020 May;35(5):783-794. PMID: 32219509
 - Giannini R, Zucchelli G, Giordano M, Ugolini C, Moretto R, Ambryszewska K, Leonardi M, Sensi E, Morano F, **Pietrantonio F**, Cremolini C, Falcone A, Fontanini G. [Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation](#). J Mol Diagn. 2020 May;22(5):685-698 PMID: 32173570
 - Malapelle U, Parente P, Pepe F, De Luca C, Cerino P, Covelli C, Balestrieri M, Russo G, Bonfitto A, Pisapia P, Fiordelisi F, D'Armiento M, Bruzzese D, Loupakis F, **Pietrantonio F**, Triassi M, Fassan M, Troncone G, Graziano P. [Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study](#). Cells. 2020 2;9:2019. PMID: 32887373.
 - Volpi CC, **Pietrantonio F**, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L. Author Correction: [The landscape of d16HER2 splice variant expression across HER2-positive cancers](#). Sci Rep. 2020 Apr 24;10(1):7210. PMID: 32332837
 - Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, **Pietrantonio F**; [Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial](#). ITACA-S study group. Oncologist. 2020 Mar;25(3):e460-e468. PMID: 32162808
 - **Pietrantonio F**, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M, de Braud F. [Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer](#). Clin Cancer Res. 2020 Mar 1;26(5):1017-1024. PMID: 31740551

- **Pietrantonio F.** Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. *N Engl J Med.* 2020 Feb 27;382(9):876-877. PMID: 32101677
- **Pietrantonio F,** Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clin Colorectal Cancer.* 2020;19:156-164. PMID: 32513593.
- Corallo S, Fucà G, Morano F, Salati M, Spallanzani A, Gloghini A, Volpi CC, Trupia DV, Lobefaro R, Guarini V, Milione M, Cattaneo L, Antista M, Prisciandaro M, Raimondi A, Sposito C, Mazzaferro V, de Braud F, **Pietrantonio F,** Di Bartolomeo M. Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. *Oncologist.* 2020;25 :780-786.PMID: 32272500.

2019

- Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, **Pietrantonio F,** Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncol.* 2019 Mar 1;5(3):343-350. PMID: 30476968
- **Pietrantonio F,** Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *J Clin Oncol.* 2019 Dec 10;37(35):3392-3400. PMID: 31513484
- Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, **Pietrantonio F,** Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Zirano P, Cascinu S. Gastric cancer: Translating novels concepts into clinical practice. *Cancer Treat Rev.* 2019 Sep;79:101889. PMID: 31445415
- Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, **Pietrantonio F.** The Landscape of Actionable Gene Fusions in Colorectal Cancer. *Int J Mol Sci.* 2019 Oct 25;20(21):5319. PMID: 31731495
- **Pietrantonio F,** Randon G, Romagnoli D, Di Donato S, Benelli M, de Braud F. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. *Cancer Treat Rev.* 2020 Jan;82:101935. PMID: 31821983
- **Pietrantonio F,** Yaeger R, Schrock AB, Randon G, Romero-Cordoba S, Rossini D, Fucà G, Ross JS, Kotani D, Madison R, Kim ST, Salvatore L, Raimondi A, Pagani F, Borelli B, Perrone F, Di Bartolomeo M, Miller VA, Ali SM, Lee J, Yoshino T, de Braud F, Falcone A, Hechtman JF, Cremolini C. Atypical RAS Mutations in Metastatic Colorectal Cancer. *JCO Precis Oncol.* 2019 Dec;3:1-11. PMID: 35100719
- Antoniotti C, **Pietrantonio F,** Corallo S, De Braud F, Falcone A, Cremolini C. Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. *JCO Precis Oncol.* 2019 Dec;3:1-14. PMID: 35100685
- Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. *Eur J Surg Oncol.* 2021 Jan;47(1):4-10. Epub 2019 Mar 23. PMID: 30954350
- Volpi CC, **Pietrantonio F,** Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L. The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Sci Rep.* 2019 Mar 5;9(1):3545. PMID: 30837627
- Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, **Pietrantonio F.** Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clin Colorectal Cancer.* 2019 Jun;18(2):e179-e190. PMID: 31023524
- Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, **Pietrantonio F.** Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Sci Rep.* 2019 Feb 27;9(1):2858. PMID: 30814645
- Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D'Errico L, Menegon S, Moya-Rull D, Cargnelutti M, Capelôa T, Conticelli D, Giordano J, Venesio T, Balsamo A, Marchiò C, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, **Pietrantonio F,** Morano F, Siena S, Sartore-Bianchi A, Bencivenga M, Mengardo V, Rosati R, Marrelli D, Morgagni P, Rausei S, Pallabazzer G, De Simone M, Ribero D, Marsoni S, Sottile A, Medico E, Cassoni P, Sapino A,

CV dott. Filippo Pietrantonio - 2025 -

- Pectasides E, Thorner AR, Nag A, Drinan SD, Wollison BM, Bass AJ, Giordano S. [A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits](#). Cancer Res. 2019 Nov 15;79(22):5884-5896. PMID: 31585941
- Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, **Pietrantonio F**, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S. [Corrigendum to "Gastric cancer: Translating novels concepts into clinical practice" \[Cancer Treatm. Rev. 79C \(2019\) 101889\]](#). Cancer Treat Rev. 2019 Dec;81:101932. PMID: 31771795
 - Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, **Pietrantonio F**, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. [A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study](#). Eur J Cancer. 2019 Sep;118:121-130. PMID: 31330487
 - Crisafulli G, Mussolin B, Cassingena A, Montone M, Bartolini A, Barault L, Martinetti A, Morano F, **Pietrantonio F**, Sartore-Bianchi A, Siena S, Di Nicolantonio F, Marsoni S, Bardelli A, Siravegna G. [Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients](#). ESMO Open. 2019 Nov;4(6):e000572. PMID: 32149725
 - Loupakis F, Biason P, Prete AA, Cremolini C, **Pietrantonio F**, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smirardo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. [CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer](#). Br J Cancer. 2019 Oct;121(7):593-599. PMID: 31474758
 - Modest DP, Rivera F, Bachet JB, de Braud F, **Pietrantonio F**, Koukakis R, Demonty G, Douillard JY. [Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials](#). Int J Cancer. 2019 Jul 15;145(2):576-585. PMID: 30614531
 - Nichetti F, Falvella FS, Miceli R, Cheli S, Gaetano R, Fucà G, Infante G, Martinetti A, Antoniotti C, Falcone A, Di Bartolomeo M, Cremolini C, de Braud F, **Pietrantonio F**. [Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?](#) Pharmacogenomics J. 2019 Oct;19(5):465-472. PMID: 30713338
 - Miceli R, An J, Di Bartolomeo M, Morano F, Kim ST, Park SH, Choi MG, Lee JH, Raimondi A, Fucà G, Sohn TS, Bae JM, Kim S, Lim DH, Kang WK, Kim KM, **Pietrantonio F**, Lee J. [Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial](#). Oncology. 2019;97(1):38-43. PMID: 31048579
 - Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, **Pietrantonio F**, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. [Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization](#). Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. PMID: 30967421
 - Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, Vernieri C, Morelli D, Dotti K, Fiordoliva I, Rinaldi S, Gavazzi C, **Pietrantonio F**, Platania M, de Braud F. [Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study](#). Sci Rep. 2019 Sep 10;9(1):12993. PMID: 31506579
 - Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, **Pietrantonio F**. [Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy](#). J Clin Oncol. 2019 Nov 20;37(33):3099-3110. PMID: 31539295
 - Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassinetti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, **Pietrantonio F**. [Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial](#). BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3. PMID: 30922323
 - Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, **Pietrantonio F**, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. [DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients](#). Pharmacogenomics J. 2019 Dec;19(6):556-563. PMID: 30723313
 - Moretto R, Morano F, Ongaro E, Rossini D, **Pietrantonio F**, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, de Braud F, Falcone A, Cremolini C. [Lack of Benefit From Anti-EGFR Treatment in](#)

RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clin Colorectal Cancer. 2019 Jun;18(2):116-124. PMID: 30952563

- **Pietrantonio F**, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smirardo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Sep 1;5(9):1268-1275. PMID: 31268481
- Rimassa L, Bozzarelli S, **Pietrantonio F**, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. PMID: 30846365
- Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, **Pietrantonio F**. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. ESMO Open. 2019 May 9;4(2):e000496. PMID: 31231562
- Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, **Pietrantonio F**. Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open. 2019 Mar 8;4(2):e000489. PMID: 30962964

2018

- Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Ceglie MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, **Pietrantonio F**. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. Eur J Cancer. 2019 Jan;107:164-174. Epub 2018 Dec 19 PMID: 30579113
- Raimondi A, Nichetti F, Peverelli G, Di Bartolomeo M, De Braud F, **Pietrantonio F**. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. Pharmacogenomics. 2018 Aug 1;19(13):1047-1068. PMID: 30041572
- **Pietrantonio F**, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. Epub 2018 Nov 24. PMID: 30558859
- De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, **Pietrantonio F**, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. Cytokine Growth Factor Rev. 2018 Dec;44:1-10. Epub 2018 Oct 30. PMID: 30393044
- Volpi CC, Gualeni AV, **Pietrantonio F**, Vaccher E, Carbone A, Gloghini A. Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. Expert Rev Mol Diagn. 2018 Mar;18(3):259-277. PMID: 29431533
- Migliore C, Morando E, Ghiso E, Anastasi S, Leoni VP, Apicella M, Cora' D, Sapino A, **Pietrantonio F**, De Braud F, Columbano A, Segatto O, Giordano S. miR-205 mediates adaptive resistance to MET inhibition via ERFF1 targeting and raised EGFR signaling. EMBO Mol Med. 2018 Sep;10(9):e8746. PMID: 30021798
- Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, **Pietrantonio F**, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerrata L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist. 2018 Feb;23(2):272. PMID: 29449512
- Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, **Pietrantonio F**, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S. Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metab. 2018 Dec 4;28(6):848-865.e6. PMID: 30174307
- Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Barattelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, **Pietrantonio F**.

-
- [Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.](#) Ann Oncol. 2017 Dec 1;28(12):3009-3014. PMID: 29045518
 - Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, **Pietrantonio F**, Siena S, Di Nicolantonio F, Bardelli A. [Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.](#) Nat Commun. 2018 Jun 12;9(1):2287 PMID: 29895949
 - Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, **Pietrantonio F**, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. [Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.](#) Target Oncol. 2018 Apr;13(2):227-234. PMID: 29582224
 - Guaglio M, Sinukumar S, Kusamura S, Milione M, **Pietrantonio F**, Battaglia L, Guadagni S, Baratti D, Deraco M. [Ann Correction to: Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms \(LAMN\) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series.](#) Surg Oncol. 2018 Dec;25(Suppl 3):987. PMID: 29352430
 - **Pietrantonio F**, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. [Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram.](#) Oncology. 2018;95(6):344-352. PMID: 30130791
 - Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, **Pietrantonio F**. [Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.](#) Eur J Cancer. 2019 Jan;107:164-174. PMID: 30579113.
 - Battaglin F, Schirripa M, Buggin F, **Pietrantonio F**, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. [The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.](#) BMC Cancer. 2018 Jan 25;18(1):98. PMID: 29370781
 - Dieci MV, Massari F, Giusti R, Inno A, Lombardi G, Noto L, Passaro A, **Pietrantonio F**, Spada F, Valente M, Di Maio M, Torri V. [Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology \(AIOM\).](#) ESMO Open. 2018 Oct 21;3(6):e000389. PMID: 30425842
 - **Pietrantonio F**. [Recenti \[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.\].](#) Prog Med. 2018 Nov;109(11):27e-29e. PMID: 30565585
 - Cremolini C, Rossini D, Martinelli E, **Pietrantonio F**, Lonardi S, Noventa S, Tamburini E, Frassinetti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A. [Trifluridine/Tipiracil \(TAS-102\) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.](#) Oncologist. 2018 Oct;23(10):1178-1187. doi: 10.1634/theoncologist.2017-0573. Epub 2018 May 8. PMID: 29739893
 - Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruner G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, **Pietrantonio F**. [Temozolomide and irinotecan \(TEMIRI regimen\) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.](#) Ann Oncol. 2018 Aug 1;29(8):1800-1806. PMID: 29860358
 - Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, **Pietrantonio F**, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, Falcone A. [TRILETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.](#) ESMO Open. 2018 Jul 9;3(4):e000403. PMID: 30018814
 - **Pietrantonio F**, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. [RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.](#) Ann Oncol. 2018 Jun 1;29(6):1394-1401. PMID: 29538669
 - Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, **Pietrantonio F**. [Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.](#) Br J Cancer. 2018 Apr;118(7):955-965. PMID: 29531324

- **Pietrantonio F.** [\[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin-based treatment due to potentially resectable liver metastases\].](#) *Recenti Prog Med.* 2018 Nov;109(11):24e-26e. PMID: 30565584
- **Pietrantonio F.** [\[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases\].](#) *Recenti Prog Med.* 2018 Nov;109(11):20e-23e. PMID: 30565583

2017

- Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, **Pietrantonio F**, Di Nicolantonio F, Bardelli A. [Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.](#) *Nature.* 2017 Dec 7;552(7683):116-120. PMID: 29186113
- **Pietrantonio F**, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. [ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.](#) *J Natl Cancer Inst.* 2017 Dec 1;109(12). PMID: 29370427
- Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R, Pellegrinelli A, Testi A, **Pietrantonio F**, Fucà G, Wei G, Murphy D, Siena S, Isacchi A, De Braud F. [Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.](#) *Oncotarget.* 2017 Jul 24;8(33):55353-55360. PMID: 28903424
- Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, **Pietrantonio F**, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. [Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.](#) *Future Oncol.* 2017 Oct;13(25):2265-2275. PMID: 28976226
- Cremolini C, **Pietrantonio F**, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Zampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. [Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.](#) *ESMO Open.* 2017 Aug 10;2(3):e000241. PMID: 29209533
- **Pietrantonio F**, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M. [Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.](#) *Clin Cancer Res.* 2018 Mar 1;24(5):1082-1089. PMID: 29208673
- Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, **Pietrantonio F**, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. [Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.](#) *Oncologist.* 2017 Dec;22(12):1463-1469. PMID: 28860412
- Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, **Pietrantonio F**, Di Nicolantonio F. [Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.](#) *Br J Cancer.* 2017 Jul 25;117(3):347-352 PMID: 28654634
- Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, **Pietrantonio F**, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest. [TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.](#) *BMC Cancer.* 2017 Jun 9;17(1):408. PMID: 28599628
- Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, Dallera P, de Braud F, Pezzica E, Di Bartolomeo M, Sgroi G, Mazzaferro V, **Pietrantonio F**, Barni S. [Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.](#) *J Gastrointest Oncol.* 2017 Feb;8(1):148-163. PMID: 28280619
- Di Salvatore M, **Pietrantonio F**, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C. [IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.](#) *Oncotarget.* 2017 Mar 7;8(10):16887-16898. PMID: 28129643
- Baratti D, Kusamura S, Iusco D, Gimondi S, **Pietrantonio F**, Milione M, Guaglio M, Bonomi S, Grassi A, Virzi S, Leo E, Deraco M. [Ann Hyperthermic Intraperitoneal Chemotherapy \(HIPEC\) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases.](#) *Surg Oncol.* 2017 Jan;24(1):167-175. PMID: 27519353
- **Pietrantonio F**, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretta M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta

- G, Falcone A, de Braud F, Cremolini C. [Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram](#). Ann Oncol. 2017 Mar 1;28(3):555-561. PMID: 27864220
- Guaglio M, Sinukumar S, Kusamura S, Milione M, **Pietrantonio F**, Battaglia L, Guadagni S, Baratti D, Deraco M. [Ann Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms \(LAMN\) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series](#). Surg Oncol. 2018 Apr;25(4):878-884. PMID: 29270877
 - Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, **Pietrantonio F**, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. [Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer](#). Eur J Cancer. 2017 Nov;86:197-206. PMID: 28992563
 - Sartore-Bianchi A, **Pietrantonio F**, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S. [Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients](#). Eur J Cancer. 2017 Jan;71:43-50. PMID: 27997874
 - Berenato R, Morano F, **Pietrantonio F**, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M. [Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions](#). Oncology. 2017;93(5):279-286. PMID: 28881354
- 2016**
- Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, **Pietrantonio F**, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G. [Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world](#). Gastric Cancer. 2017 Sep;20(5):825-833. Epub 2016 Dec 27 PMID: 28028664
 - Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, **Pietrantonio F**, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. [Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest](#). Eur J Cancer. 2017 Mar;73:74-84. Epub 2016 Dec 13 PMID: 27986363
 - Cremolini C, **Pietrantonio F**. [How the lab is changing our view of colorectal cancer](#). Tumori. 2016 Dec 1;102(6):541-547. PMID: 27647226
 - Vernieri C, Casola S, Foiani M, **Pietrantonio F**, de Braud F, Longo V. [Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions](#). Cancer Discov. 2016 Dec;6(12):1315-1333. PMID: 27872127
 - Cremolini C, Antoniotti C, **Pietrantonio F**, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, Braud F, Loupakis F, Falcone A, Di Maio M. [Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis](#). Cancer Res Treat. 2017 Jul;49(3):834-845. Epub 2016 Nov 15. PMID: 27857020
 - **Pietrantonio F**, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V. [Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases](#). Clin Colorectal Cancer. 2017 Sep;16(3):e191-e198. Epub 2016 Oct 6. PMID: 27979717
 - **Pietrantonio F**, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, Morano F, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, Baratti D, Bowne WB, Kusamura S, Deraco M. [Toward the molecular dissection of peritoneal pseudomyxoma](#). Ann Oncol. 2016 Nov;27(11):2097-2103. Epub 2016 Aug 8. PMID: 27502722
 - Giampieri R, Caporale M, **Pietrantonio F**, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. [Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?](#) Crit Rev Oncol Hematol. 2016 Apr;100:99-106. PMID: 26907512
 - Baratti D, Kusamura S, **Pietrantonio F**, Guaglio M, Niger M, Deraco M. [Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review](#). Crit Rev Oncol Hematol. 2016 Apr;100:209-22. PMID: 26867984
 - Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di Bartolomeo M, Clementi E, Loupakis F, **Pietrantonio F**. [Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab](#). Pharmacogenomics J. 2017 Jul;17(4):331-336. Epub 2016 Mar 22. PMID: 27001121
 - Petrelli F, Coinu A, Zaniboni A, **Pietrantonio F**, Barni S. [Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis](#). Rev Recent Clin Trials. 2016;11(1):56-62. PMID: 26282898

CV dott. Filippo Pietrantonio - 2025 -

- Iacovelli R, **Pietrantonio F**, Maggi C, de Braud F, Di Bartolomeo M. [Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials](#). Crit Rev Oncol Hematol. 2016 Feb;98:24-8. PMID: 26481953
- Baratti D, Kusamura S, Milione M, **Pietrantonio F**, Caporale M, Guaglio M, Deraco M. Ann [Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study](#). Surg Oncol. 2016 Dec;23(13):4222-4230. PMID: 27352203
- **Pietrantonio F**, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. [Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer](#). Target Oncol. 2016 Jun;11(3):337-43. PMID: 26538496
- Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, **Pietrantonio F**, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. [Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer](#). Nat Commun. 2016 Dec 8;7:13665. PMID: 27929064
- **Pietrantonio F**, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F. [Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer](#). Clin Cancer Res. 2017 May 15;23(10):2414-2422. Epub 2016 Oct 25. PMID: 27780856
- Di Bartolomeo M, **Pietrantonio F**, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I, Miceli R. [Osteopontin, E-cadherin, and \$\beta\$ -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer](#) Gastric Cancer. 2016 Apr;19(2):412-420. PMID: 25862567
- Di Bartolomeo M, **Pietrantonio F**, Rulli E, Poli D, Berenato R, Caporale M, Bajetta E, Floriani I. [Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer](#). Tumori. 2016 Aug 3;102(4):e15-9. PMID: 27032700
- **Pietrantonio F**, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V. [Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases](#). Clin Colorectal Cancer. 2017 Sep;16(3):e191-e198. PMID: 27979717
- Baratti D, Kusamura S, Iusco D, Gimondi S, **Pietrantonio F**, Milione M, Guaglio M, Bonomi S, Grassi A, Virzi S, Leo E, Deraco M. Ann [Hyperthermic Intraperitoneal Chemotherapy \(HIPEC\) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases](#). Surg Oncol. 2017 Jan;24(1):167-175. PMID: 27519353
- Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, **Pietrantonio F**, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. [Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest](#). Eur J Cancer. 2017 Mar;73:74-84. PMID: 27986363
- **Pietrantonio F**, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F. [MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer](#). Cancer Discov. 2016 Sep;6(9):963-71. PMID: 27325282
- Moretto R, Cremolini C, Rossini D, **Pietrantonio F**, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A. [Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer](#). Oncologist. 2016 Aug;21(8):988-94. PMID: 27382031
- **Pietrantonio F**, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F. [GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study](#). J Transl Med. 2016 May 6;14(1):125. PMID: 27154293

2015

- Baratti D, Kusamura S, Maggi C, de Braud F, Deraco M, Di Bartolomeo M, **Pietrantonio F**. [In reply](#). Oncologist. 2015 Mar;20(3):e5. PMID: 25745055
- Orlandi A, Calegari A, Inno A, Berenato R, Caporale M, Niger M, Bossi I, Di Bartolomeo M, de Braud F, **Pietrantonio F**. [BRAF in metastatic colorectal cancer: the future starts now](#). Pharmacogenomics. 2015 Dec;16(18):2069-81. PMID: 26615988
- Di Bartolomeo M, Maggi C, Ricchini F, **Pietrantonio F**, Iacovelli R, de Braud F, Inno A. [Bevacizumab treatment in the elderly patient with metastatic colorectal cancer](#). Clin Interv Aging. 2015 Jan 5;10:127-33. PMID: 25584021
- Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E, **Pietrantonio F**. [Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase](#). Int J Mol Sci. 2015 Apr 21;16(4):8884-95. PMID: 25906475

- **Pietrantonio F**, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, Antoniotti C, de Braud F, Falcone A, Iacovelli R. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015 Oct;96(1):156-66. PMID: 26088456
- Iacovelli R, **Pietrantonio F**, Maggi C, de Braud F, Di Bartolomeo M. Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. Crit Rev Oncol Hematol. 2016 Feb;98:24-8. PMID: 26481953
- **Pietrantonio F**, Orlandi A, Inno A, Da Prat V, Spada D, Iaculli A, Di Bartolomeo M, Morosi C, de Braud F. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. Crit Rev Oncol Hematol. 2015 Sep;95(3):272-81. PMID: 25958297
- **Pietrantonio F**, Petrelli F, Coinu A, Di Bartolomeo M, Borronovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015 Mar;51(5):587-94. PMID: 25673558
- Petrelli F, **Pietrantonio F**, Cremolini C, Di Bartolomeo M, Coinu A, Lonati V, de Braud F, Barni S. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. Eur J Cancer. 2015 May;51(7):800-7. PMID: 25794604
- Cremolini C, Di Maio M, Petrelli F, Berenato R, Loupakis F, **Pietrantonio F**. BRAF-mutated metastatic colorectal cancer between past and future. Br J Cancer. 2015 Dec 1;113(11):1634-5. PMID: 26355234
- Cheli S, **Pietrantonio F**, Clementi E, Falvella FS. LightSNiP assay is a good strategy for pharmacogenetics test. Front Pharmacol. 2015 Jun 2;6:114. PMID: 26082719
- Di Bartolomeo M, **Pietrantonio F**, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I, Miceli R. Osteopontin, E-cadherin, and β -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 2016 Apr;19(2):412-420. PMID: 25862567
- **Pietrantonio F**, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F, Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, de Braud F. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol. 2015 Jul;32(7):182. PMID: 26003673
- **Pietrantonio F**, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Nigam M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiother Oncol. 2015 Nov;117(2):315-21 PMID: 26347495
- Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, de Braud F, Clementi E, **Pietrantonio F**. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015 Sep;80(3):581-8. PMID: 25782327.
- Musella V, **Pietrantonio F**, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I, Maggi C, Di Bartolomeo M, de Braud F, Daidone MG, Cappelletti V. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer. 2015 Sep 15;137(6):1467-74. PMID: 25704501
- **Pietrantonio F**, Cremolini C. Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al. Ann Oncol. 2015 Nov;26(11):2353. Epub 2015 Sep 7. PMID: 26347099
- Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, **Pietrantonio F**. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015 Oct;26(10):2092-7. Epub 2015 Jul 7. PMID: 26153495
- Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, **Pietrantonio F**, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015 Sep;26(9):1994-1999. Epub 2015 Jun 25. PMID: 26113646
- Di Bartolomeo M, Ciarlo A, Bertolini A, Barni S, Verusio C, Aitini E, **Pietrantonio F**, Iacovelli R, Dotti KF, Maggi C, Perrone F, Bajetta E. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. Eur J Cancer. 2015 Mar;51(4):473-481. PMID: 25637137
- **Pietrantonio F**, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal

CV dott. Filippo Pietrantonio - 2025 -

Cancer: Challenging Drug Label to Light Up New Hope. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. PMID: 26446234

2014

- Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de Braud F, Bossi I, **Pietrantonio F.** Role of MGMT as biomarker in colorectal cancer. World J Clin Cases. 2014 Dec 16;2(12):835-9. PMID: 25516857
- Miceli R, Tomasello G, Bregni G, Di Bartolomeo M, **Pietrantonio F.** Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol. 2014 Apr 28;20(16):4516-25. PMID: 24782604
- **Pietrantonio F,** Iacovelli R, Di Bartolomeo M, de Braud F. FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncol. 2014 Dec;15(13):e581. PMID: 25456372
- Iacovelli R, **Pietrantonio F,** Farcomeni A, Maggi C, Palazzo A, Ricchini F, de Braud F, Di Bartolomeo M. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies PLoS One. 2014 Sep 30;9(9):e108940. PMID: 25268988
- Iacovelli R, **Pietrantonio F,** Palazzo A, Maggi C, Ricchini F, de Braud F, Di Bartolomeo M. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol. 2014 Dec;78(6):1228-37. PMID: 24962653
- **Pietrantonio F,** Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M, Perrone F, Baratti D, Kusamura S, Tamborini E, Castano A, Consonni PV, Bossi I, Gavazzi C, Milione M, Pelosi G, de Braud F. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist. 2014 Aug;19(8):845-50. Epub 2014 Jun 20. PMID: 24951608
- **Pietrantonio F,** Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F. TP53 mutations in advanced colorectal cancer: the dark side of the moon. Oncology. 2014;86(5-6):289-94. PMID: 24924261
- Falvella FS, Cheli S, de Braud F, Clementi E, **Pietrantonio F.** Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. Per Med. 2014 May;11(3):259-262. PMID: 29764069
- Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, **Pietrantonio F.** Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel). 2014 Aug 29;6(3):1753-68. PMID: 25256831
- Bajetta E, **Pietrantonio F,** Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. Am J Clin Oncol. 2014 Dec;37(6):545-9. PMID: 23428953
- **Pietrantonio F,** Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS One. 2014 Apr 1;9(4):e92147. PMID: 24691006
- Cortinovis D, Monica V, **Pietrantonio F,** Ceresoli GL, La Spina CM, Wannesson L. MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. Curr Pharm Des. 2014;20(24):3982-90. PMID: 24138721

2013

- **Pietrantonio F,** Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol. 2014 Feb;25(2):404-8. Epub 2013 Dec 29. PMID: 24379162
- Samamé Pérez-Vargas JC, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, **Pietrantonio F.** Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 2013 Sep 3;14(9):18056-77. PMID: 24005867
- **Pietrantonio F,** Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol. 2013;30(3):610. PMID: 23700226
- Di Bartolomeo M, **Pietrantonio F,** Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol. 2014 Jun;9(2):155-62. Epub 2013 Jul 3. PMID: 23821376
- **Pietrantonio F,** De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013 Apr;33(4):1257-66. PMID: 23564763
- Fanetti G, Ferrari LA, **Pietrantonio F,** Buzzoni R. Reversible bilateral blepharoptosis following oxaliplatin infusion: a case report and literature review. Tumori. 2013 Sep-Oct;99(5):e216-9. PMID: 24501793

CV dott. Filippo Pietrantonio - 2025 -

- **Pietrantonio F**, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F, Tondulli L, Ferrari D, Ricci V, Villa F, Barone G, Bianco N, Ghidini A, Bossi I, Fanetti G, Di Bartolomeo M, de Braud F. [Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy](#). Cancer Biol Ther. 2013 Dec;14(12):1098-103. PMID: 24025413
- Bampo C, Alessi A, Fantini S, Bertarelli G, de Braud F, Bombardieri E, Valvo F, Crippa F, Di Bartolomeo M, Mariani L, Milione M, Biondani P, Avuzzi B, Chiruzzi C, **Pietrantonio F**. [Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?](#) Oncology. 2013;84(4):191-9. PMID: 2332839

2012

- Díaz-Rubio E, **Pietrantonio F**, de Braud F. [Continuing single-agent bevacizumab as maintenance therapy after induction XELOX \(or FOLFOX\) plus bevacizumab in first-line treatment of metastatic colorectal cancer](#). Oncologist. 2012;17(11):1426-8. PMID: 23073991
- Biondani P, Procopio G, **Pietrantonio F**, de Braud F, Verzoni E. [New perspectives in advanced genitourinary malignancies](#). Tumori. 2012 Mar-Apr;98(2):267-9. PMID: 22677996
- **Pietrantonio F**, Biondani P, Pellegrinelli A, Marchianò A, Dotti KF, Buzzoni R, Di Bartolomeo M. [Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab](#). Med Oncol. 2012 Dec;29(4):2838-41. PMID: 22271433
- **Pietrantonio F**, Biondani P, Milione M, Melotti F, Bertarelli G, Perrone F, de Braud F, Mariani L, Fanetti G, Cortinovis D, Di Bartolomeo M. [Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients](#). Clin Transl Oncol. 2013 Jul;15(7):582-6. Epub 2012 Nov 21. PMID: 23180349
- **Pietrantonio F**, Garassino MC, Torri V, de Braud F. [Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306](#). Ann Oncol. 2012 Oct;23(10):2771-2772. Epub 2012 Aug 8. PMID: 22875835
- **Pietrantonio F**, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M. [Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen](#). Transl Oncol. 2012 Jun;5(3):155-9. PMID: 22741034
- **Pietrantonio F**, Biondani P, Verzoni E, Procopio G. [Management of advanced genitourinary tumors](#). Tumori. 2012 Mar-Apr;98(2):264-6. PMID: 22677995

2011

- Di Bartolomeo M, **Pietrantonio F**, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. [Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer](#). Drugs Aging. 2011 Feb 1;28(2):83-91. PMID: 21155618
- Platania M, Agustoni F, Formisano B, Vitali M, Ducceschi M, **Pietrantonio F**, Zilembo N, Gelsomino F, Pusceddu S, Buzzoni R. [Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer](#). Target Oncol. 2011 Sep;6(3):181-6. PMID: 21667119

2010

- Zilembo N, Vitali M, **Pietrantonio F**, Platania M, Del Vecchio M, Bajetta E. [An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review](#). Tumori. 2010 Nov-Dec;96(6):1031-4. PMID: 21388071
- **Pietrantonio F**, Di Bartolomeo M, Buzzoni R, Bajetta E. [Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report](#). Tumori. 2010 Jan-Feb;96(1):154-6. PMID: 20437874
- Zilembo N, Vitali M, **Pietrantonio F**, Platania M, Del Vecchio M, Bajetta E. [An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review](#). Tumori. 2010 Nov-Dec;96(6):1031-4. PMID: 21388071
- Di Bartolomeo M, **Pietrantonio F**, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. [Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer](#). Drugs Aging. 2011 Feb 1;28(2):83-91. PMID: 21155618

Competenze Linguistiche:

Italiano	Madrelingua
Inglese	Eccellente
Spagnolo	Buono

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document. I authorize the treatment of my personal data according to the Art. 13 of the EU regulation 2016/679